These concerns are real, and they deserve a real answer, not a dismissive “don’t worry about it” or a complicated lecture about clinical trials. So let me walk you through what we actually know, what we don’t know, and what it means for you.

Where does this fear come from?

In 2012, the FDA added a warning to statin labels about potential memory problems. This made headlines. Patients got scared. Doctors got questions. And a lot of people stopped taking their statins.

But here’s what most news stories didn’t explain: the FDA based this warning on reports that patients and doctors voluntarily submitted - not on controlled studies designed to test whether statins actually affect memory. When someone reports a side effect while taking a medication, that doesn’t prove the medication caused it. It just means the two things happened around the same time.

Think of it this way: millions of people start statins in their 50s and 60s. That’s also the age when memory naturally starts to change for everyone—statin or no statin. If you happen to notice your memory slipping after starting a statin, it’s natural to connect the two. But that connection might be coincidence, not cause.

So researchers set out to test this properly.

What happens when you actually test this carefully?

The gold standard in medicine is called a randomized controlled trial. You take a large group of people, randomly assign half to get the real medication and half to get a placebo (a dummy pill), and then compare what happens—without anyone knowing which pill they got. This removes the bias of expectation.

When researchers combined the results of 25 such trials involving nearly 47,000 people, they found something clear: people taking statins performed exactly the same on memory and thinking tests as people taking placebo pills. No difference. Not even a small trend toward harm. This held true whether people had normal memory to begin with or already had Alzheimer’s disease. (Ott et al., 2015)

A larger analysis looked at 33 studies with over 128,000 people. Same finding. Despite dramatically lowering cholesterol, statins didn’t change rates of memory problems or dementia. The only measurable difference? People on statins actually performed slightly better on tests of mental speed. (Ying et al., 2020)

These aren’t small studies done by drug companies. These are independent researchers combining decades of data, looking specifically for harm - and not finding it.

So why do so many people feel foggy on statins?

This is where it gets interesting and it involves something called the nocebo effect.

You’ve probably heard of the placebo effect: give someone a sugar pill but tell them it’s pain medication, and some of them will actually feel less pain. Their expectation creates a real physical experience.

The nocebo effect is the opposite. Tell someone a medication might cause headaches, and some of them will get headaches—even if they’re taking a sugar pill.

A remarkable study demonstrated this with statins. Researchers in the UK followed over 10,000 people, first in a phase where neither patients nor doctors knew who was getting atorvastatin versus placebo, and then in a phase where everyone knew.

During the blinded phase, when nobody knew who was on the real drug, muscle complaints were identical in both groups ~ 2% per year. Cognitive problems were too rare to even measure meaningfully.

But during the unblinded phase, when people knew they were taking a statin, muscle complaints suddenly jumped 41% higher in the statin group. The medication hadn’t changed. Only awareness of taking it had changed. (Gupta et al., Lancet 2017)

This doesn’t mean people are making up their symptoms. Nocebo effects are real experiences in your body: real pain, real fog, real fatigue. But they’re generated by expectation and anxiety rather than by the chemistry of the drug itself.

When you’ve read scary articles about statins and memory, when your neighbor told you her husband “was never the same” after starting one, when you’re already worried about getting older, your brain is primed to notice and attribute any mental hiccup to the pill.

Can statins actually protect the brain?

Here’s something that might surprise you: if anything, the evidence leans toward statins being good for your brain, not bad.

This makes sense when you think about what statins do. They lower cholesterol, yes, but they also reduce inflammation and improve blood vessel health throughout your body—including the blood vessels feeding your brain. Many types of dementia, including some cases of Alzheimer’s, involve problems with blood flow to the brain. A medication that keeps blood vessels healthy might protect against this.

Long-term studies following older adults for up to 12 years found that statin users were actually less likely to have the protein deposits (called amyloid) associated with Alzheimer’s disease. Statin use wasn’t associated with faster memory decline or higher dementia rates. (Arvanitakis et al., 2008)

Now, this doesn’t prove statins prevent Alzheimer’s. These were observational studies, meaning we’re watching what happens to people who chose to take statins versus those who didn’t, and those groups might differ in other ways. But it’s reassuring that after following tens of thousands of people for years, researchers keep finding either no effect or a slight benefit, never clear harm.

What about people who already have memory problems?

Researchers also tested whether giving statins to people with diagnosed Alzheimer’s disease would help or hurt.

In the largest such trial, 640 patients with mild to moderate Alzheimer’s took either high-dose atorvastatin or placebo for 72 weeks while continuing their other Alzheimer’s medications. The result? No difference. The statin didn’t help their memory, but it didn’t hurt it either. (Feldman et al., Neurology 2010)

This fits a pattern: statins seem neutral for the brain. They don’t appear to accelerate decline, but they don’t reverse existing damage either. Their potential value is probably in prevention—keeping blood vessels healthy over decades—rather than treatment once problems have started.

The brain makes its own cholesterol

One reason people worry about statins and the brain involves a misunderstanding about cholesterol.

Your brain contains about 25% of your body’s total cholesterol, even though it’s only 2% of your body weight. Cholesterol is essential for brain cells to function—it’s part of every cell membrane and helps nerve signals travel.

But here’s the key point most people don’t know: your brain makes its own cholesterol. The cholesterol in your blood can’t cross into your brain. There’s a barrier—the blood-brain barrier—that prevents this. So the cholesterol your statin is lowering in your bloodstream isn’t the same pool of cholesterol your brain uses.

Statins do get into the brain to some degree and can affect cholesterol production there. But the brain has backup systems and tightly regulates its own cholesterol supply. In most people, this system handles statin exposure without any problem. (Allen et al., 2019)

Could some people genuinely be more sensitive?

Honesty requires acknowledging what we don’t fully understand.

Most people tolerate statins without any effect on their thinking. The large trials prove this at the population level. But medicine treats individuals, not populations, and some individuals do report real improvement when they stop their statin. What might explain this?

One clue comes from the differences between statins themselves. Statins aren’t all identical. Some like simvastatin and atorvastatin—dissolve easily in fat, which means they can slip into the brain more readily. Others like pravastatin and rosuvastatin—dissolve in water and have a harder time crossing from blood into brain tissue. A review examining all available evidence found that the rare reports of cognitive trouble came mostly from the fat-soluble statins, not the water-soluble ones. (Rojas-Fernandez et al., 2012)

This makes biological sense. Your brain makes its own cholesterol and tightly controls its supply. A statin that can’t easily get into the brain won’t affect this process. A statin that penetrates more deeply might—in some people—temporarily interfere with the brain’s cholesterol production.

Research in mice helps explain what might happen in that sensitive minority. When researchers gave mice simvastatin (a fat-soluble statin) for extended periods, they found the drug did reduce cholesterol levels in the hippocampus—the brain region crucial for memory—and the mice performed worse on memory tasks. But here’s the important part: when they stopped the drug, the brain’s cholesterol levels returned to normal, the connections between brain cells recovered, and the memory problems disappeared. (Guo et al., 2021)

This reversibility is reassuring. Even in an animal model specifically designed to show statin effects on the brain, the changes weren’t permanent. Stop the drug, and the brain bounces back.

What does this mean practically? If you’re one of the rare individuals who genuinely experiences cognitive changes on a statin, you have options beyond simply stopping all cholesterol treatment:

You can try a different statin. Switching from a fat-soluble statin like simvastatin or atorvastatin to a water-soluble one like pravastatin or rosuvastatin might eliminate the problem while still protecting your heart. Several clinical reports suggest this works. (Rojas-Fernandez et al., 2012)

You can use a lower dose. The degree to which any statin affects the brain likely depends on how much reaches brain tissue—which depends partly on blood levels. Lower doses mean less drug available to cross into the brain.

You can add or switch to non-statin alternatives. Medications like ezetimibe block cholesterol absorption from your gut—they never even reach your brain. PCSK9 inhibitors work in your liver and don’t cross into the brain either. Combining a low-dose statin with these alternatives can achieve the same cholesterol-lowering while minimizing brain exposure.

The bottom line: even if you’re among the small minority who might be sensitive to statin effects on the brain, this isn’t a binary choice between protecting your heart and protecting your memory. The medical toolkit has expanded. And importantly, the evidence suggests that any cognitive effects from statins are reversible—your brain isn’t being permanently changed.

What if you’re convinced your statin is affecting your memory?

Take your concern seriously, but approach it carefully.

First, consider timing. Did your symptoms truly start with the statin, or were you already noticing changes that you’ve now attributed to the medication? Memory changes are common in middle age regardless of medication.

Second, consider the nocebo effect. If you’ve been anxious about statins, that anxiety itself can cause fatigue, difficulty concentrating, and mental fog. Anxiety is exhausting, and exhaustion makes thinking harder.

Third, talk to your doctor about a trial off the medication. This means stopping the statin for a defined period (usually a few weeks to a couple months) to see if your symptoms genuinely improve. If they do, you might try restarting to see if they return. If symptoms improve off the statin and worsen when you restart it, that’s meaningful information—even if it contradicts the population data.

Fourth, remember that alternatives exist. If you and your doctor conclude that you truly can’t tolerate a statin, other medications can lower cholesterol without affecting cholesterol production: ezetimibe blocks cholesterol absorption from food; PCSK9 inhibitors help your liver clear cholesterol from blood; bempedoic acid works earlier in the pathway than statins. You don’t have to choose between your brain and your heart.

The honest answer

Here’s what I’d tell my own family member asking this question:

The fear that statins cause memory problems is understandable but not supported by the evidence. When scientists have tested this carefully in tens of thousands of people, they’ve found no harm. Many people who believe their statin is causing brain fog are likely experiencing the nocebo effect—real symptoms caused by expectation and worry rather than by the drug’s chemistry.

At the same time, if you have persistent, bothersome cognitive symptoms that you strongly associate with your statin, it’s reasonable to discuss a trial discontinuation with your doctor. You’re not crazy. Your experience matters. But go into that conversation knowing that the odds favor a cause other than the statin.

For most people, statins remain among the most proven, safest, most effective medications we have for preventing heart attacks and strokes. The risk of stopping them is real and measurable. The risk of cognitive harm is theoretical and undetectable in large studies.

What we still don’t know

I want to be honest about the limits of our knowledge.

Until recently, no trial was specifically designed to answer the dementia question as its main purpose. The older trials looked at heart disease first and cognition second. But researchers recognized this gap—two major trials—STAREE (Zoungas et al., 2024) in Australia and PREVENTABLE (Joseph et al., 2023) in the United States—have enrolled nearly 30,000 older adults specifically to answer whether statins affect dementia risk.

We also don’t know whether starting a statin in your 40s versus your 70s makes a difference for brain health. We don’t know whether certain statins are better or worse for the brain than others. We don’t know whether people with certain genetic profiles respond differently.

These gaps should be filled with research, not fear. In the meantime, the preponderance of evidence says statins are safe for your brain—and the evidence of their heart benefits is overwhelming.

Thanks for reading and subscribing to Signal Over Noise.

If you found this helpful, please share it with anyone who’s worried about this question. Getting accurate information out matters—and it might help someone avoid stopping a medication that’s protecting their heart.

All content on Signal Over Noise is free and open-access.

Share

References

1. Ott BR, et al. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med. 2015;30(3):348-58.

   DOI: 10.1007/s11606-014-3115-3

2. Ying H, et al. Association of Statin Use With Risk of Dementia and Mild Cognitive Impairment. JAMA Network Open. 2020.

   DOI: 10.1001/jamanetworkopen.2020.15222

3. Gupta A, et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the ASCOT-LLA trial. Lancet. 2017;389(10088):2473-2481.

   DOI: 10.1016/S0140-6736(17)31075-9

4. Ruscica M, et al. Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications. Cardiovasc Res. 2023;118(17):3288-3304.

   DOI: 10.1093/cvr/cvac020

5. Feldman HH, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010;74(12):956-64.

   DOI: 10.1212/WNL.0b013e3181d6476a

6. Arvanitakis Z, et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology. 2008;70(19):1795-802.

   DOI: 10.1002/ana.21422

7. Allen LB, et al. Desmosterol and Desmosterolosis. Prostaglandins Leukot Essent Fatty Acids. 2019;143:1-4.

   DOI: 10.1016/j.plefa.2019.02.002

8. Bai X, et al. The role of DHCR24 in the pathogenesis of AD: re-cognition of the relationship between cholesterol and AD pathogenesis. Acta Neuropathol Commun. 2022;10(1):35.

   DOI: 10.1186/s40478-022-01338-3

9. Power MC, et al. Statins, cognition, and dementia—systematic review and methodological commentary. Nat Rev Neurol. 2015;11(4):220-9.

   DOI: 10.1038/nrneurol.2015.35

10. Wagstaff LR, et al. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003;23(7):871-80.

    DOI: 10.1592/phco.23.7.871.32720

11. Moon JY, et al. Characteristics of Subjective and Objective Statin-Related Adverse Events. Clin Pharmacol Ther. 2020;107(3):630-637.

    DOI: 10.1002/cpt.1671

12. Bitzur R. Remembering Statins: Do Statins Have Adverse Cognitive Effects? Diabetes Care. 2016;39 Suppl 2:S253-9.

    DOI: 10.2337/dcS15-3022

13. Zoungas S. STAREE investigator group. Baseline Characteristics of Participants in STAREE: A Randomized Trial for Primary Prevention of Cardiovascular Disease Events and Prolongation of Disability-Free Survival in Older People. J Am Heart Assoc. 2024 Nov 19;13(22):e036357. doi: 10.1161/JAHA.124.036357. Epub 2024 Nov 15.

    https://pubmed.ncbi.nlm.nih.gov/39548016/

14. Joseph J. Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale. J Am Geriatr Soc. 2023 Jun;71(6):1701-1713. doi: 10.1111/jgs.18312. Epub 2023 Apr 20.

    https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/jgs.18312

The most comprehensive systematic assessment to date—a 2020 Cochrane meta-analysis encompassing 86 randomized trials and over 162,000 participants—delivers a sobering conclusion. According to this analysis, increasing intake of long-chain omega-3 fatty acids (EPA and DHA) shows little or no effect on all-cause mortality (RR 0.97, 95% CI 0.93–1.01) or total cardiovascular events (RR 0.96, 95% CI 0.92–1.01) based on high-certainty evidence (Abdelhamid et al., Cochrane 2020). The data suggest possible modest reductions in coronary heart disease events (NNT 167) and coronary mortality (NNT 334), but these effects carry only low-certainty evidence and evaporate in sensitivity analyses restricted to low-bias trials.

The VITAL trial reinforced this disappointment. In nearly 26,000 adults without prior cardiovascular disease, standard-dose marine omega-3 supplementation (1 g/day) over 5.3 years produced no significant reduction in the primary composite endpoint compared to placebo (HR 0.92, 95% CI 0.80–1.06). However, a notable 28% reduction in myocardial infarction was observed (HR 0.72, 95% CI 0.59–0.90)—a secondary endpoint that complicates any simple dismissal (Manson et al., NEJM 2019).

The STRENGTH trial delivered similarly null results: among 13,078 high-risk patients with atherogenic dyslipidemia, a carboxylic acid formulation of EPA plus DHA showed no benefit over corn oil for major adverse cardiovascular events (HR 0.99, 95% CI 0.90–1.09) (Nicholls et al., JAMA 2020).

Yet one trial defied this pattern. REDUCE-IT, funded by Amarin Pharma, randomized 8,179 patients with established cardiovascular disease or diabetes to high-dose icosapent ethyl (4 g/day of purified EPA) versus mineral oil placebo. The results were striking: a 25% relative reduction in the primary composite endpoint (HR 0.75, 95% CI 0.68–0.83), corresponding to an absolute risk reduction of 4.8 percentage points (22.0% vs 17.2%) and a number needed to treat of approximately 21 over 4.9 years. Cardiovascular death was also reduced by 20% (Bhatt et al., NEJM 2019). An updated meta-analysis confirmed dose-response relationships for cardiovascular outcomes (Hu et al., JAHA 2019).

How do we reconcile these findings? Both REDUCE-IT and STRENGTH face legitimate methodological questions. The mineral oil placebo in REDUCE-IT has drawn criticism for potentially raising LDL and inflammatory markers, which could inflate apparent benefit. Conversely, STRENGTH’s corn oil comparator contains linoleic acid—itself potentially cardioprotective—possibly obscuring any omega-3 effect. Neither comparator was truly inert.

The answer may lie not in whether omega-3s work, but in which formulation, at what dose, and in whom. REDUCE-IT used highly purified EPA at pharmacological doses in patients with elevated triglycerides—a distinct intervention from over-the-counter fish oil capsules in the general population. Recent imaging data suggest EPA, but not EPA/DHA combinations, reduces coronary plaque burden (Sheppard et al., Acta Cardiol 2025). Whether EPA’s apparent benefit stems from triglyceride lowering, anti-inflammatory effects, membrane stabilization, or mechanisms yet unidentified remains uncertain. The increased atrial fibrillation observed with icosapent ethyl (3.1% vs 2.1%) also warrants consideration.

For now, the message is nuanced: generic fish oil supplements for primary prevention lack convincing evidence of benefit. High-dose prescription icosapent ethyl may reduce cardiovascular events in select high-risk patients with elevated triglycerides despite statin therapy—though at the cost of increased arrhythmia risk. Between these poles lies considerable uncertainty, and a reminder that biological plausibility cannot substitute for rigorous trial data.

Share

If you liked what you read share it.

Subscribe now

References

1. Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial. JAMA. 2021 Apr 13;325(14):1403–13.

2. Grill HJ. A role for GLP-1 in treating hyperphagia and obesity. Endocrinology [Internet]. 2020 Aug 1;161(8). Available from: http://dx.doi.org/10.1210/endocr/bqaa093

3. Safwan M, Bourgleh MS, Alotaibi SA, Alotaibi E, Al-Ruqi A, El Raeya F. Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis. Ann Saudi Med. 2025 Mar;45(2):129–43.

4. Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA. 2021 Apr 13;325(14):1414–25.

5. Berg S, Stickle H, Rose SJ, Nemec EC. Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis. Obes Rev. 2025 Aug;26(8):e13929.

6. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023 Dec 14;389(24):2221–32.

7. Wilbon SS, Kolonin MG. GLP1 receptor agonists-effects beyond obesity and diabetes. Cells. 2023 Dec 28;13(1):65.

Subscribe now

This is not a fringe concern. It’s not an artifact of cherry-picked data. And it’s not something we should dismiss with a wave of the hand. The question isn’t whether this effect exists—it does—but rather what it means, why it happens, and how we should incorporate it into clinical decision-making.

The Data That Changed the Conversation

The alarm bells first rang clearly in 2010 when Sattar and colleagues published a landmark meta-analysis in The Lancet, pooling individual patient data from 13 major statin trials involving over 91,000 participants (1). The finding: statin therapy was associated with a 9% increased risk of developing diabetes (odds ratio 1.09; 95% CI 1.02–1.17). In absolute terms, treating 255 patients with a statin for four years resulted in one additional case of diabetes.

That 9% figure has proven remarkably durable. Subsequent analyses have either confirmed it or, in some cases, suggested the risk may appear even higher in real-world populations. A 2017 meta-analysis of 20 observational studies found a 44% increased risk of new-onset diabetes among statin users compared with non-users (relative risk 1.44; 95% CI 1.31–1.58) (2).

However, this observational estimate should be interpreted cautiously. The dramatic discrepancy between the 9% RCT estimate and the 44% observational figure likely reflects confounding by indication—the very factors that lead physicians to prescribe statins (obesity, metabolic syndrome, elevated cardiovascular risk) also independently predispose patients to diabetes. Observational studies also suffer from surveillance bias: patients on statins receive more frequent blood tests, so diabetes gets detected earlier. The RCT estimate of 9% is almost certainly closer to the true causal effect, while the larger observational signal reflects the reality that statin-treated populations already carry elevated metabolic risk.

What’s more, the effect appears dose-dependent. A network meta-analysis of 29 trials examining individual statins found that high-dose atorvastatin (80 mg) carried the highest diabetes risk (OR 1.34; 95% CI 1.14–1.57), followed by rosuvastatin (OR 1.17; 95% CI 1.02–1.35) (3). Pravastatin appeared genuinely neutral (OR 1.04; 95% CI 0.93–1.16). Data on pitavastatin suggest possible neutrality, though estimates remain imprecise due to limited trial data (OR 0.74; 95% CI 0.31–1.77—a confidence interval spanning nearly six-fold). The overall pattern is consistent with what we’d expect from a mechanism tied to LDL-lowering potency—the more aggressively you lower LDL, the greater the metabolic perturbation.

Why This Happens: Following the Biology

For years, researchers debated whether the diabetes risk was an on-target effect of statins—directly related to how they work—or an off-target side effect unrelated to cholesterol lowering. Mendelian randomization studies have provided strong evidence favoring the on-target hypothesis, though the question isn’t entirely closed.

When researchers examined genetic variants in the HMGCR gene—which encodes the very enzyme that statins inhibit—they found that people with naturally lower HMGCR activity (and therefore lower LDL cholesterol from birth) also had higher glucose levels, higher body weight, and increased diabetes risk (4). This genetic evidence suggests the diabetes signal isn’t an accident or an impurity in the drug—it appears to be linked to the mechanism itself. That said, Mendelian randomization has its own limitations, including potential horizontal pleiotropy (where genetic variants affect outcomes through multiple pathways), and findings from lifelong genetic exposure may not perfectly predict the effects of pharmacological intervention started in middle age.

The biological pathways are becoming clearer nonetheless. Statins appear to impair glucose homeostasis through at least two distinct routes, both stemming from inhibition of the mevalonate pathway—the same pathway that produces cholesterol.

First, there’s the effect on insulin secretion. Pancreatic beta cells require certain downstream products of the mevalonate pathway—particularly isoprenoids like geranylgeranyl pyrophosphate—for normal insulin release. When statins block mevalonate synthesis, these isoprenoids become depleted, and beta-cell function suffers (5). There’s also evidence that statins interfere with calcium channel signaling in beta cells, which is essential for stimulus-secretion coupling.

Second, statins impair insulin sensitivity in peripheral tissues. Reduced translocation of glucose transporter 4 (GLUT4) to the cell membrane—the molecular step that allows muscle and fat cells to take up glucose—has been demonstrated in statin-treated cells. The net result: higher circulating glucose and greater insulin demand on an already stressed pancreas (6).

A comprehensive 2023 review in Frontiers in Endocrinology synthesized this evidence, describing a two-pronged mechanism: reduced insulin secretion combined with increased insulin resistance—a combination that nudges susceptible individuals toward diabetes (7).

Who Is Most Vulnerable?

Not everyone faces equal risk. The diabetes signal concentrates among individuals who were already on the path toward metabolic dysfunction. In the JUPITER trial—a large primary prevention study of rosuvastatin—researchers stratified participants by pre-existing diabetes risk factors: metabolic syndrome, impaired fasting glucose, obesity (BMI ≥30), or elevated hemoglobin A1c (8).

Among those with at least one such risk factor, statin therapy was associated with a 28% increase in new-onset diabetes (hazard ratio 1.28; 95% CI 1.07–1.54). Among those with no diabetes risk factors, the increase was essentially absent (HR 0.99; 95% CI 0.45–2.21). The message is clear: if you’re metabolically healthy, statins don’t appear to push you into diabetes. But if you’re already prediabetic, already carrying excess weight, already showing early signs of insulin resistance—statins may accelerate the timeline.

Meta-regression analyses from the original Sattar meta-analysis also identified older age as a risk factor for statin-associated diabetes, though the data on other demographic factors (sex, race) remain less definitive. What we can say with confidence is that the patients at highest metabolic risk at baseline are the ones most likely to develop diabetes on statin therapy—which creates a clinical tension, since these same patients often derive the greatest cardiovascular benefit from treatment.

The Calculus That Matters: Benefits vs. Risks

Here is where clinical judgment enters the picture. We don’t prescribe statins to avoid diabetes—we prescribe them to prevent heart attacks and strokes. The question is whether the cardiovascular benefits outweigh the diabetes hazard.

The JUPITER trial provides perhaps the most granular answer. Among participants with diabetes risk factors who took rosuvastatin, 134 vascular events or deaths were prevented for every 54 new diabetes cases diagnosed. That’s roughly a 2.5:1 benefit-to-risk ratio. Among those without diabetes risk factors, 86 vascular events were prevented with no new diabetes cases—essentially all benefit, no metabolic cost.

To put this in perspective: the number needed to treat (NNT) to cause one additional diabetes case over four years is 255. The NNT to prevent one major cardiovascular event in high-risk populations is typically in the range of 20–50. In other words, for every diabetes case induced, statins prevent roughly 5–10 heart attacks, strokes, or cardiovascular deaths. The arithmetic strongly favors treatment.

Moreover, the JUPITER analysis revealed a finding that should reassure patients: even among the 486 participants who developed new diabetes during the trial, the cardiovascular benefit of statin therapy was preserved. Those who developed diabetes on rosuvastatin still saw a 37% relative reduction in vascular events (HR 0.63; 95% CI 0.25–1.60)—a point estimate consistent with the overall trial, though the wide confidence interval reflects the smaller sample size in this subgroup.

What about the nature of the diabetes itself? The JUPITER data showed that statin therapy accelerated the average time to diabetes diagnosis by 5.4 weeks—from 89.7 weeks on placebo to 84.3 weeks on rosuvastatin. One interpretation is that statins unmask latent diabetes rather than creating it de novo, accelerating the diagnosis in people who were already headed toward metabolic dysfunction. However, from the patient’s perspective, earlier onset of a chronic disease remains a meaningful consequence, regardless of whether it was “inevitable.” Both framings have merit: the diabetes is real, but it likely would have developed anyway—just slightly later.

Practical Implications for Patients and Clinicians

None of this should be used as a reason to withhold statins from patients at elevated cardiovascular risk. The data are unambiguous: statins prevent cardiovascular events, and that benefit substantially exceeds the diabetes risk across nearly every population studied.

What this evidence does demand is vigilance. Patients initiating statin therapy—particularly those with metabolic risk factors—should have baseline glucose or A1c measured and periodic reassessment. For most patients, this means an annual metabolic panel. For those with prediabetes, more frequent monitoring may be appropriate.

It also invites a conversation. Patients have a right to understand that statins, like all medications, carry trade-offs. The honest framing is this: Statins modestly increase the likelihood that your body will develop diabetes—most often in people who were already headed that direction. But they substantially decrease your risk of having a heart attack or stroke. For most people at cardiovascular risk, the math strongly favors treatment.

For patients particularly concerned about diabetes risk, lifestyle optimization becomes even more important: weight management, physical activity, dietary improvement. These interventions reduce both cardiovascular risk and diabetes risk simultaneously, and they make the decision to use statins easier by shrinking the potential downside.

Some have asked whether certain statins are “safer” from a metabolic standpoint. The data on pravastatin are reassuring—it appears genuinely neutral on glucose metabolism. Pitavastatin may also be favorable, though the evidence base is thinner and confidence intervals are wide. For patients at particularly high diabetes risk who require statin therapy, these agents deserve consideration, provided equally effective cardiovascular protection can be achieved. However, head-to-head comparative trials powered specifically for diabetes outcomes don’t exist, so switching statins based solely on marginally different metabolic signals remains a judgment call rather than an evidence-based mandate.

The Bottom Line

Statins increase the risk of diabetes. This is not a controversy—it’s an established finding supported by randomized trials, observational studies, and genetic evidence. The effect is modest in absolute terms (roughly 9% relative increase, or one case per 255 patients treated for four years), concentrated among those already at metabolic risk, and appears mechanistically linked to the very pathway through which statins save lives.

What makes this finding tolerable—even acceptable—is the simple arithmetic of benefit and harm. The cardiovascular events prevented far outnumber the diabetes cases induced. And for those who do develop diabetes on statin therapy, the cardiovascular protection persists.

The responsible approach is neither denial nor alarm. It’s transparency: patients deserve to understand both the benefits and the risks of their medications. It’s monitoring: we can catch glucose elevations early and intervene with lifestyle or treatment. And it’s perspective: in the grand calculus of cardiovascular risk, statins remain one of our most valuable tools.

For the millions of patients at elevated cardiovascular risk, the case for statin therapy remains strong. The diabetes signal is real, but it doesn’t change the conclusion—it just reminds us that in medicine, nothing is free.

If you found this analysis valuable, please share it.

Evidence over opinions. Clarity over noise. That’s Signal Over Noise.

Share

References

1. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet [Internet]. 2010 Feb 27;375(9716):735–42.

2. Casula M, Mozzanica F, Scotti L, Tragni E, Pirillo A, Corrao G, et al. Statin use and risk of new-onset diabetes: A meta-analysis of observational studies. Nutr Metab Cardiovasc Dis [Internet]. 2017 May;27(5):396–406.

3. Thakker D, Nair S, Pagada A, Jamdade V, Malik A. Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiol Drug Saf [Internet]. 2016 Oct;25(10):1131–49.

4. Swerdlow DI, Preiss D. Genetic insights into statin-associated diabetes risk. Curr Opin Lipidol [Internet]. 2016 Apr;27(2):125–30.

5. Brault M, Ray J, Gomez YH, Mantzoros CS, Daskalopoulou SS. Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metabolism [Internet]. 2014 Jun;63(6):735–45.

6. Carmena R, Betteridge DJ. Diabetogenic action of statins: Mechanisms. Curr Atheroscler Rep [Internet]. 2019 Apr 30;21(6):23.

7. Laakso M, Fernandes Silva L. Statins and risk of type 2 diabetes: mechanism and clinical implications. Front Endocrinol (Lausanne) [Internet]. 2023 Sep 19;14:1239335.

8. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet [Internet]. 2012 Aug 11;380(9841):565–71.

If this sounds absurd, congratulations. You’ve just experienced what the diet wars feel like from the inside.

The study wasn’t a prank. It was designed to test the “Lipid Energy Model” in a specific phenotype called Lean Mass Hyper-Responders—metabolically healthy individuals whose LDL skyrockets on ketogenic diets. The Oreos weren’t magic. They provided 100 grams of carbohydrates that shifted the metabolic machinery away from fat oxidation. The point wasn’t that Oreos are healthy. The point was that context determines everything.

And yet, this single case study has been wielded by low-carb critics as evidence that keto is dangerous, and by keto advocates as evidence that LDL elevation on their diet is mechanistically distinct and therefore benign. Same data. Opposite conclusions. Welcome to the diet wars.

The tribal landscape

Vegans cite research showing plant-based diets reduce cardiovascular disease. Carnivores cite research showing red meat associations are weak and confounded. Keto enthusiasts cite diabetes reversal data. Mediterranean diet proponents cite the only large RCT with hard cardiovascular endpoints. Each tribe has PhDs, peer-reviewed papers, and passionate certainty.

The problem isn’t that any of them are lying. The problem is that nutrition science is genuinely difficult, and motivated reasoning is genuinely easy.

Most diet studies are observational. People who choose to eat plant-based differ from people who choose carnivore in dozens of ways beyond their food choices—exercise habits, smoking rates, socioeconomic status, health consciousness. Adjusting for confounders helps, but residual confounding persists. And even randomized trials struggle with adherence, blinding (you know if you’re eating steak or tofu), and the impossibility of running 20-year studies on hard endpoints like heart attacks and death.

So what do we actually know? Let me walk through the major diet camps and the highest-quality evidence for each.

The Mediterranean diet: the closest thing to a winner

If any dietary pattern has earned the right to claim cardiovascular benefit, it’s the Mediterranean diet. The PREDIMED trial randomized 7,447 high-risk Spanish adults to either a Mediterranean diet supplemented with extra-virgin olive oil, a Mediterranean diet supplemented with mixed nuts, or a control diet with advice to reduce fat. After a median follow-up of 4.8 years, both Mediterranean arms showed roughly 30% reduction in major adverse cardiovascular events compared to control.(2)

The trial was stopped early because the benefit was clear. A 2024 meta-analysis pooling PREDIMED with three other RCTs (Lyon Diet Heart Study, Indo-Mediterranean Diet Heart Study, CORDIOPREV) found that Mediterranean diet reduced the composite of MI, stroke, and cardiovascular death by 48% (OR 0.52, 95% CI 0.32-0.84) (3). Stroke risk dropped by 37%. Cardiovascular mortality dropped by 46%.

This is the gold standard. Randomized. Hard endpoints. Replicated across multiple trials. The Mediterranean diet is not a fad. It is the only dietary pattern with this level of evidence for cardiovascular protection.

Critics note that PREDIMED had some randomization irregularities in a subset of participants, leading to a retraction and republication with corrected analyses. The corrections didn’t meaningfully change the results. A comprehensive review in Circulation Research concluded that the criteria for causality were met and the evidence is “large, strong, and consistent” (4).

Plant-based diets: real benefits, real gaps

Vegetarian and vegan diets have accumulated substantial observational evidence. A 2022 meta-analysis of 13 cohort studies involving 844,175 participants found that vegetarians had 15% lower risk of cardiovascular disease (RR 0.85) and 21% lower risk of ischemic heart disease compared to non-vegetarians (5). The association with IHD was deemed “probably causal” using rigorous WCRF criteria.

But there’s a catch. The same meta-analysis found no significant reduction in stroke risk among vegetarians. And a 2023 European Heart Journal review made a crucial distinction: not all plant-based foods are equally healthy (6). Diets rich in refined grains, sugary beverages, and processed vegetarian foods show increased mortality despite being technically “plant-based.” The quality of plant foods matters as much as the absence of animal foods.

I see B12 deficiency regularly in my practice. In India, where vegetarianism is culturally prevalent, this isn’t rare—it’s common. Prolonged deficiency causes irreversible neurological damage. Iron, zinc, and calcium deficiencies also occur with poorly planned vegetarian diets. These aren’t theoretical concerns. They’re clinical realities that don’t make it into the advocacy literature.

The evidence supports well-planned plant-based diets for cardiovascular risk reduction. It does not support the claim that eliminating all animal products is necessary or universally optimal.

The ketogenic diet: metabolic benefits, lipid concerns

Ketogenic diets produce rapid, measurable improvements in several metabolic markers. A 2023 umbrella review in BMC Medicine synthesized 17 meta-analyses covering 68 randomized trials (7). The findings were telling.

High-certainty evidence showed that ketogenic diets reduce triglycerides and reduce seizure frequency in epilepsy. Moderate-certainty evidence showed reductions in body weight, HbA1c, and respiratory exchange ratio. For weight loss and glycemic control, particularly in type 2 diabetes, the short-term data are favorable.

But the same umbrella review found high-certainty evidence that ketogenic diets increase LDL cholesterol. This is not a minor footnote. LDL elevation is the most robustly established causal risk factor for atherosclerotic cardiovascular disease. The authors concluded: “Clinical trials with long-term follow-up are warranted to investigate whether the short-term effects of KD will translate to beneficial effects on clinical outcomes such as cardiovascular events and mortality.”

We don’t have those trials. The keto community often dismisses LDL concerns by pointing to improvements in triglycerides and HDL. But the ratio doesn’t override the absolute LDL risk in populations with established cardiovascular disease. In my practice, I’ve seen patients on ketogenic diets with LDL levels exceeding 300-400 mg/dL. These are not numbers I can ignore, regardless of how good their triglyceride-to-HDL ratio looks.

The lean mass hyper-responder puzzle

The most intellectually honest keto advocates acknowledge the LDL problem and point to emerging research on Lean Mass Hyper-Responders. These are metabolically healthy, often lean individuals whose LDL rises dramatically on carbohydrate restriction—sometimes exceeding 500 mg/dL—while maintaining very high HDL and very low triglycerides.

The KETO-CTA trial, published in JACC Advances in 2024, compared 80 such individuals (mean LDL 272 mg/dL, some as high as 591 mg/dL) to matched controls with average LDL of 123 mg/dL (8). Using coronary CT angiography, the researchers found no significant difference in plaque burden between groups. No correlation between LDL level and plaque. In a 2025 follow-up with longitudinal imaging, they reported that baseline plaque predicted plaque progression, but ApoB and LDL exposure did not (9).

This is genuinely surprising and deserves attention. But context matters. The mean duration on ketogenic diet was 4.7 years. Atherosclerosis develops over decades. The sample was 80 people—highly selected, metabolically exceptional individuals. And coronary plaque on CT is a surrogate marker, not a hard clinical endpoint. We don’t know if these individuals will have more heart attacks in 20 years.

The LMHR data is hypothesis-generating. It suggests that the relationship between LDL and cardiovascular risk may be context-dependent in ways we don’t fully understand. It does not prove that sky-high LDL is safe in any population. The authors themselves emphasized that their findings “should provoke further research and not be seen as health advice.”

Red meat and the carnivore question

The carnivore diet—eating exclusively animal products—has no randomized trial data on cardiovascular outcomes. Its proponents rely primarily on critiques of observational studies linking red meat to disease.

Those critiques aren’t baseless. A 2019 systematic review in Annals of Internal Medicine analyzed 61 articles from 55 cohorts with over 4 million participants (10). The authors concluded that the association between red and processed meat consumption and adverse cardiometabolic outcomes is “very small” and the evidence is “of low certainty.” This paper generated enormous controversy precisely because it challenged dietary guidelines that many considered settled.

A 2020 JAMA Internal Medicine study of 29,682 US adults found that each additional 2 servings per week of unprocessed red meat was associated with a 3% increased risk of incident cardiovascular disease (11). Statistically significant, but the absolute risk increase was small—about 0.6% over 30 years. Processed meat showed slightly stronger associations.

The honest summary: observational data consistently show small associations between red meat intake and cardiovascular risk. The magnitude is modest. The certainty is low. Confounding is substantial. We have no RCT evidence on carnivore diets and hard endpoints, and we’re unlikely to get any.

Absence of evidence is not evidence of safety. Advocates who claim carnivore diets are optimal for cardiovascular health are extrapolating far beyond what the data support.

What actually matters

After reviewing the highest-quality evidence from tier-1 journals, a few conclusions survive the tribal warfare.

First, dietary patterns matter more than single nutrients or foods. The Mediterranean diet’s benefit likely comes from the overall pattern—olive oil, nuts, fish, vegetables, legumes, moderate wine—not from any single component. Obsessing over whether eggs raise cholesterol or whether saturated fat is “actually fine” misses the forest for the trees.

Second, ultra-processed foods are probably the real enemy. Across dietary ideologies, from plant-based to paleo, the consistent signal is that whole, minimally processed foods outperform their industrial counterparts. An unhealthy vegetarian diet heavy in refined carbs and processed meat alternatives increases mortality. A keto diet built on processed cheese and bacon is not the same as one built on fish, avocado, and olive oil.

Third, individual variation is real but poorly understood. The LMHR phenotype demonstrates that the same diet produces different metabolic responses in different people. We’re only beginning to understand why. Precision nutrition remains more promise than reality, but it’s not wrong to acknowledge that dietary recommendations may need individualization.

Fourth, long-term data on hard endpoints remain scarce for most diets. The Mediterranean diet has it. Plant-based diets have supportive observational data. Ketogenic and carnivore diets have metabolic studies and surrogate markers. Anyone claiming certainty about 20-year cardiovascular outcomes from these latter diets is overstating the evidence.

The boring truth

The diet wars persist because uncertainty is uncomfortable and tribal identity is appealing. It’s more satisfying to believe you’ve found the One True Diet than to acknowledge that nutrition science is messy, context-dependent, and evolving.

The Oreo study that opened this piece wasn’t evidence that cookies are healthy. It was a mechanistic demonstration in a single unusual patient. But it became a weapon in tribal combat within hours of publication. That’s how the diet wars work. Data becomes ammunition. Context becomes collateral damage.

As a cardiologist, my job isn’t to pick a dietary tribe. It’s to read the evidence carefully, acknowledge uncertainty honestly, and help patients make decisions that fit their metabolic reality, their preferences, and their risk profile. For most people, that means something closer to Mediterranean than to any extreme—more plants, more olive oil, more fish, fewer processed foods, and less obsession with dietary purity.

The science isn’t as exciting as the wars. But it’s more useful.

If you found this analysis valuable, please share it.

Evidence over opinions. Clarity over noise. That’s Signal Over Noise.

1. Norwitz NG, Cromwell WC. Oreo cookie treatment lowers LDL cholesterol more than high-intensity statin therapy in a Lean Mass Hyper-responder on a ketogenic diet: A curious crossover experiment. Metabolites. 2024 Jan 22;14(1):73.

2. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin Olive oil or nuts. N Engl J Med. 2018 Jun 21;378(25):e34.

3. Sebastian SA, Padda I, Johal G. Long-term impact of mediterranean diet on cardiovascular disease prevention: A systematic review and meta-analysis of randomized controlled trials. Curr Probl Cardiol. 2024 May;49(5):102509.

4. Martínez-González MA, Gea A, Ruiz-Canela M. The Mediterranean diet and cardiovascular health: A critical review. Circ Res. 2019 Mar;124(5):779–98.

5. Dybvik JS, Svendsen M, Aune D. Vegetarian and vegan diets and the risk of cardiovascular disease, ischemic heart disease and stroke: a systematic review and meta-analysis of prospective cohort studies. Eur J Nutr. 2023 Feb;62(1):51–69.

6. Wang T, Masedunskas A, Willett WC, Fontana L. Vegetarian and vegan diets: benefits and drawbacks. Eur Heart J. 2023 Sep 21;44(36):3423–39.

7. Patikorn C, Saidoung P, Pham T, Phisalprapa P, Lee YY, Varady KA, et al. Effects of ketogenic diet on health outcomes: an umbrella review of meta-analyses of randomized clinical trials. BMC Med. 2023 May 25;21(1):196.

8. Budoff M, Manubolu VS, Kinninger A, Norwitz NG, Feldman D, Wood TR, et al. Carbohydrate restriction-induced Elevations in LDL-cholesterol and Atherosclerosis: The KETO trial. JACC Adv. 2024 Aug;3(8):101109.

9. Soto-Mota A, Norwitz NG, Manubolu VS, Kinninger A, Wood TR, Earls J, et al. Longitudinal data from the KETO-CTA study: Plaque predicts plaque, ApoB does not. JACC Adv. 2025 Jul;4(7):101686.

10. Zeraatkar D, Han MA, Guyatt GH, Vernooij RWM, El Dib R, Cheung K, et al. Red and processed meat consumption and risk for all-cause mortality and cardiometabolic outcomes: A systematic review and meta-analysis of cohort studies: A systematic review and meta-analysis of cohort studies. Ann Intern Med. 2019 Nov 19;171(10):703–10.

11. Zhong VW, Van Horn L, Greenland P, Carnethon MR, Ning H, Wilkins JT, et al. Associations of processed meat, unprocessed red meat, poultry, or fish intake with incident cardiovascular disease and all-cause mortality. JAMA Intern Med. 2020 Apr 1;180(4):503–12.

Prevention felt like trench warfare. We won significant battles with statins in the 1970s and 1980s, effectively neutralizing LDL cholesterol. We gained ground with antihypertensives. We even cut smoking rates. Yet despite these victories, the enemy kept advancing. Obesity and type 2 diabetes continued to climb, acting as twin accelerants on the vascular system.

For decades, the pharmacological tools to fight obesity were either dangerous or embarrassing. Fen-phen damaged heart valves (1). Orlistat resulted in gastrointestinal humiliation. Bariatric surgery worked but was mechanically invasive and framed as a desperate last resort.

When GLP-1 receptor agonists first appeared, the medical establishment largely pigeonholed them as just another diabetes drug. They were expected to lower hemoglobin A1c, perhaps cause a little weight loss, and stay in their endocrinology lane. Then the cardiovascular outcome trials began to land, and the silo walls collapsed.

The Biology of the Whisper

To understand why this class of drugs has upended cardiology, you need to understand the hormone itself. Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by L-cells in the distal intestine in response to nutrient intake. In its native state, GLP-1 is ephemeral. It survives for only 1 to 2 minutes in the bloodstream before being degraded by dipeptidyl peptidase-4 (DPP-4) (2). In its natural state, GLP-1 shows up after you eat, does its job, and vanishes within minutes.

It nudges insulin secretion upward in a glucose-dependent manner, suppresses glucagon to stop the liver from overproducing sugar, and slows gastric emptying (3). Crucially, it also talks to the brain. Through direct action on the hypothalamus and indirect signaling via the vagus nerve, GLP-1 promotes satiety(4).

Scientists circumvented the rapid degradation of native GLP-1 by engineering analogues: molecules that mimic the hormone but resist enzymatic destruction, lasting for days or weeks. When these stable ligands flood the receptors, they don’t just lower blood sugar. They modulate the central appetite drive, which patients have started calling the “food noise.”(5)

This phrase went viral on social media not because it was marketing language but because it captured something people hadn’t been able to articulate before. Not hunger itself, but the constant mental chatter around eating. This was the first clue that we were dealing with something more profound than a glucose-lowering agent. We were manipulating fundamental neurobehavioral pathways.

The Data That Changed the Paradigm

The narrative shift from “diabetes drug” to “cardiovascular drug” was built on a foundation of rigorous, large-scale randomized controlled trials. The early signals came from diabetes cohorts. The LEADER trial demonstrated that liraglutide reduced cardiovascular death in high-risk diabetic patients (6). SUSTAIN-6 showed similar benefits with semaglutide (7), and REWIND extended these findings to a broader, lower-risk population with dulaglutide (8). Across these studies, the reduction in major adverse cardiovascular events (MACE: a composite of heart attack, stroke, and cardiovascular death) averaged around 13 to 14%.

This was impressive, but it remained tethered to diabetes. The real existential shock to the system came with the SELECT trial in 2023. SELECT asked a bold question: Could semaglutide reduce heart attacks and strokes in people who were overweight or obese but did not have diabetes? The study enrolled 17,604 patients with established cardiovascular disease. The results were unequivocal. Semaglutide 2.4 mg reduced the risk of MACE by 20% (hazard ratio 0.80, 95% CI 0.72-0.90, P<0.001)(9).

This was the turning point. The drug didn’t just fix sugar; it fixed the substrate of vascular disease itself. In SELECT, patients lost approximately 10% of their body weight, but they also saw reductions in systolic blood pressure, triglycerides, and C-reactive protein (a marker of inflammation). The data suggested that treating adiposity was practically synonymous with treating the artery.

Beyond the Heart: The Multi-Organ Benefit

The story has since expanded beyond the cardiovascular system, revealing that metabolic dysfunction is a systemic crisis, not a localized one. The kidneys, often the first casualties of diabetes and hypertension, are also protected. The FLOW trial was stopped early for efficacy, a rarity in nephrology. It showed that semaglutide significantly reduced the progression of renal failure and death in patients with type 2 diabetes and chronic kidney disease (10).

Simultaneously, hepatologists are seeing reversals in metabolic dysfunction-associated steatohepatitis (MASH), the liver manifestation of metabolic syndrome. Semaglutide has been shown to improve histological features of MASH (11).

We are witnessing a pharmacological unification theory. Heart failure, kidney disease, fatty liver, and atherosclerosis are not separate diseases requiring separate specialists. They are different faces of the same metabolic engine. GLP-1 receptor agonists tune that engine.

The Weight Loss That Matters

The magnitude of weight loss with GLP-1 receptor agonists exceeded initial expectations. The STEP 1 trial of semaglutide 2.4 mg weekly demonstrated 14.9% weight loss at 68 weeks in patients with obesity (12). The SURMOUNT-1 trial of tirzepatide (a dual GLP-1/GIP receptor agonist) achieved 20.9% weight loss with the 15 mg dose (13), surpassing any previous pharmacotherapy for obesity.

A critical question: does cardiovascular benefit derive solely from weight loss, or do GLP-1 receptor agonists exert weight-independent cardioprotection? Several lines of evidence suggest weight-independent mechanisms contribute substantially. In cardiovascular outcome trials, Kaplan-Meier curves for MACE begin diverging within months, before substantial weight loss occurs. The remaining benefit appears attributable to direct vascular, anti-inflammatory, and potentially myocardial effects.

Numbers alone rarely move people, but weight loss is not vanity in cardiology. It’s hemodynamics. A story of a patient discovering they can climb a flight of stairs without stopping conveys more truth than any hazard ratio. That is the cardiovascular math embodied.

Addressing the Noise: Safety and Controversy

No therapy this potent comes without controversy, and the cultural explosion around “Ozempic” has generated significant noise. We must distinguish between physiological risks and social media panic.

Gastrointestinal symptoms remain the most common cause of discontinuation, occurring in 20 to 40% of patients depending on dose. These symptoms are usually mild to moderate, occur early in therapy, and diminish over time. Slow dose titration substantially reduces their frequency and severity. More serious concerns, such as gastroparesis (stomach paralysis), have appeared in case reports. While rare, these underscore the need for careful patient selection and dose escalation.

The pancreatitis debate continues. While observational signals exist, meta-analyses of randomized trials have not confirmed a definitive causal link. Meta-analyses do confirm increased risk of gallbladder disease (14) likely related to rapid weight loss.

Critics frequently cite the loss of lean muscle mass as a fatal flaw. Physiologically, this is expected. Any rapid weight loss, whether surgical or dietary, involves catabolism of both fat and lean tissue. The solution is not to abandon the drug but to pair it with resistance training and adequate protein intake, standard advice for any weight management intervention.

Perhaps the most stubborn criticism is that “the weight comes back when you stop.” Withdrawal studies confirm this: patients regain substantial weight after cessation(15). This is often framed as a failure of the drug. In reality, it is proof of the disease. We don’t criticize antihypertensives because blood pressure rises when pills are stopped. We don’t mock statins because cholesterol rebounds upon discontinuation. Obesity is a chronic, relapsing neuro-metabolic disease. It requires chronic treatment.

Thyroid C-cell tumors appeared in rodent studies, leading to boxed warnings, but human evidence has not confirmed this risk after nearly two decades of use (16,17)

Who Should Consider Therapy

Current guidelines provide clear direction. The 2025 ADA Standards of Care and 2023 ESC guidelines give strong recommendations for GLP-1 receptor agonists in patients with type 2 diabetes and established atherosclerotic cardiovascular disease. For cardiologists and clinicians, several patient populations warrant consideration:

• Type 2 diabetes with established cardiovascular disease (the strongest indication)

• Obesity with established cardiovascular disease regardless of diabetes status (the SELECT population)

• Type 2 diabetes with chronic kidney disease (the FLOW population)

• BMI 30 kg/m² or greater or BMI 27 kg/m² or greater with comorbidities after lifestyle interventions have failed

  

The Horizon: Science Fiction Becoming Science Fact

We are currently only at the beginning of the incretin era. The pipeline is moving from single agonists to multi-receptor engineering. Tirzepatide has already demonstrated weight loss exceeding 20% in the SURMOUNT-1 trial, surpassing the efficacy of semaglutide(13).

Retatrutide, a “triple G” agonist (GLP-1, GIP, and glucagon), showed weight loss of 24.2% at 48 weeks with the 12 mg dose in a phase 2 trial (18). This level of efficacy was previously the exclusive domain of invasive bariatric surgery.

Oral formulations promise to break the barrier of injectability, potentially democratizing access if costs can be managed. This is where medicine starts to feel like speculative fiction, except the trials are real(19,20).

Why Lifestyle Still Matters

GLP-1 receptor agonists target the biological drivers of weight, but lifestyle addresses muscle mass, VO₂ max, sleep, mood, and metabolic resilience. All major guidelines treat medication as adjunctive to behavioral intervention. These drugs don’t replace lifestyle. They make lifestyle possible again for people whose biology has fought them for decades.

Where This Leaves Us

The arrival of effective GLP-1 therapies forces a rare moment of clarity in medicine. For years, we treated the downstream consequences of metabolic dysfunction: stenting the blocked artery, dialyzing the failed kidney, transplanting the cirrhotic liver, while the root cause remained untreated. The science now stands firm. We have clear evidence of fewer heart attacks, fewer strokes, preserved kidney function, and profound weight loss.

There will be challenges ahead. Cost poses a massive ethical dilemma, creating a rift where the wealthy access health and the vulnerable access advice. Monthly costs of $900 to $1,500 for brand-name GLP-1 receptor agonists create barriers for patients and healthcare systems. The long-term effects of decades-long use remain to be fully mapped.

But for the first time in cardiology’s history, we are not just waiting in the trenches for the enemy to attack. We are finally dismantling the engine of the disease itself. The GLP-1 era forces a conceptual shift: obesity, diabetes, cardiovascular disease, liver disease, and kidney disease are different manifestations of the same underlying metabolic engine. For the first time, we have drugs that tune that engine directly.

The cardiovascular community must take ownership of GLP-1 receptor agonist prescribing for our patients. Integration into cardiology practice, development of cardiometabolic clinics, and advocacy for appropriate coverage represent necessary next steps in translating this powerful evidence base into improved patient outcomes. The fundamental question is no longer whether GLP-1 receptor agonists reduce cardiovascular events (the evidence is definitive) but rather how we ensure that patients who would benefit actually receive them.

If you found this useful, please share it.

Evidence over opinions. Clarity over noise. That’s Signal Over Noise.

Share

References

1. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med [Internet]. 1997 Aug 28;337(9):581–8. Available from: https://doi.org/10.1056/NEJM199708283370901

2. Singh AK. Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions. Indian J Endocrinol Metab [Internet]. 2014 Nov;18(6):753–9. Available from: http://dx.doi.org/10.4103/2230-8210.141319

3. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev [Internet]. 2007 Oct;87(4):1409–39. Available from: http://dx.doi.org/10.1152/physrev.00034.2006

4. van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol [Internet]. 2014 Apr;221(1):T1–16. Available from: http://dx.doi.org/10.1530/JOE-13-0414

5. Naveed M, Perez C, Ahmad E, Russell L, Lees Z, Maybury C. GLP-1 medication and weight loss: Barriers and motivators among 1659 participants managed in a virtual setting. Diabetes Obes Metab [Internet]. 2025 July;27(7):3780–8. Available from: http://dx.doi.org/10.1111/dom.16405

6. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med [Internet]. 2016 July 28;375(4):311–22. Available from: https://doi.org/10.1056/NEJMoa1603827

7. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med [Internet]. 2016 Nov 10;375(19):1834–44. Available from: http://dx.doi.org/10.1056/NEJMoa1607141

8. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet [Internet]. 2019 July 13;394(10193):121–30. Available from: https://doi.org/10.1016/S0140-6736(19)31149-3

9. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med [Internet]. 2023 Dec 14;389(24):2221–32. Available from: https://doi.org/10.1056/NEJMoa2307563

10. Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med [Internet]. 2024 July 11;391(2):109–21. Available from: https://doi.org/10.1056/NEJMoa2403347

11. Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med [Internet]. 2021 Mar 25;384(12):1113–24. Available from: https://doi.org/10.1056/NEJMoa2028395

12. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med [Internet]. 2021 Mar 18;384(11):989–1002. Available from: https://doi.org/10.1056/NEJMoa2032183

13. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med [Internet]. 2022 July 21;387(3):205–16. Available from: https://doi.org/10.1056/NEJMoa2206038

14. Chiang CH, Jaroenlapnopparat A, Colak SC, Yu CC, Xanthavanij N, Wang TH, et al. Glucagon-like peptide-1 receptor agonists and gastrointestinal adverse events: A systematic review and meta-analysis. Gastroenterology [Internet]. 2025 Nov;169(6):1268–81. Available from: http://dx.doi.org/10.1053/j.gastro.2025.06.003

15. Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab [Internet]. 2022 Aug;24(8):1553–64. Available from: https://doi.org/10.1111/dom.14725

16. Chiu WY, Shih SR, Tseng CH. A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer. Exp Diabetes Res [Internet]. 2012 May 28;2012:924168. Available from: http://dx.doi.org/10.1155/2012/924168

17. Espinosa De Ycaza AE, Brito JP, McCoy RG, Shao H, Singh Ospina N. Glucagon-like peptide-1 receptor agonists and thyroid cancer: A narrative review. Thyroid [Internet]. 2024 Apr;34(4):403–18. Available from: http://dx.doi.org/10.1089/thy.2023.0530

18. Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. Triple-hormone-receptor agonist retatrutide for obesity - A phase 2 trial. N Engl J Med [Internet]. 2023 Aug 10;389(6):514–26. Available from: https://doi.org/10.1056/NEJMoa2301972

19. Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med [Internet]. 2023 Sept 7;389(10):877–88. Available from: http://dx.doi.org/10.1056/NEJMoa2302392

20. Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care [Internet]. 2024 Nov 1;47(11):1873–88. Available from: https://dx.doi.org/10.2337/dci24-0003

The debate has consumed social media for days. Arguments over vaccine safety, anecdotal accounts of alleged harm, and accusations of credential worship versus evidence-based medicine have dominated discourse.

Meanwhile, a separate evidence base—robust, published in top-tier journals, and endorsed by major cardiology societies—remains largely unimplemented. Influenza vaccination reduces major adverse cardiovascular events by 25-28% in high-risk populations, with cardiovascular mortality reductions of 26-41%. The efficacy is comparable to statins and antihypertensive therapy. Yet vaccination rates among cardiovascular disease patients remain between 27% and 60%.

The IAMI trial, published in Circulation in 2022, demonstrated that influenza vaccination within 72 hours of myocardial infarction reduced cardiovascular death by 41%. The mechanism appears to involve immunomodulation during the acute inflammatory period post-infarction, not simply prevention of future respiratory infections.

This is the conversation being drowned out.

The numbers that should have changed everything

In 2022, Swedish researchers tested whether influenza vaccination immediately after myocardial infarction could reduce subsequent cardiovascular events. The IAMI trial enrolled 2,571 patients hospitalized with heart attacks—both ST-elevation and non-ST-elevation MI. Half received the flu vaccine within 72 hours of admission. Half received placebo.

Over the following year, the vaccine group had 28% fewer major cardiovascular events: a composite of death, recurrent heart attack, or stent thrombosis (HR 0.72, 95% CI 0.52–0.99).

The benefit was even more pronounced for cardiovascular death specifically. Vaccinated patients had 41% lower cardiovascular mortality (HR 0.59, 95% CI 0.39–0.89). The effect was consistent whether patients had STEMI or non-STEMI.

This rapid benefit suggests the vaccine isn’t simply preventing seasonal flu infections that might occur later; it’s likely modulating the inflammatory milieu during the acute post-infarction period when atherosclerotic plaques are most unstable and thrombotic risk is highest.

To contextualize the efficacy: influenza vaccination reduces myocardial infarction risk by 15-45% across multiple studies, with cardiovascular mortality reductions ranging from 26-41% in high-risk populations. How does this compare to therapies we already prescribe religiously? Statins reduce MI risk by 19-30%. Antihypertensive therapy reduces risk by 17-25%. Smoking cessation reduces risk by 32-43%. Influenza vaccination sits comfortably within this range—yet it’s treated as optional, an afterthought. Influenza vaccination rates among cardiovascular disease patients hover between 27% and 60% depending on the region and population studied.

To understand why this matters beyond preventing respiratory infections, the biological mechanisms warrant examination.

Vaccines do more than just preventing flu

The cardioprotective effects of vaccination operate through four interconnected mechanisms.

Inflammation reduction. Acute respiratory infections trigger the release of pro-inflammatory cytokines—interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and IL-1β—that contribute directly to atherosclerotic plaque instability and rupture. Studies show that approximately 12% of patients hospitalized with influenza experience acute cardiovascular events, with acute heart failure (6.2%) and acute ischemic heart disease (5.7%) being the most common. One in four fatal influenza cases has an associated acute cardiovascular event.

Vaccination attenuates this inflammatory burden. Multi-omics analysis of COVID-19 vaccinated individuals who experienced breakthrough infections revealed significantly reduced RNA inflammatory signatures and lower levels of serum proteins associated with disease severity compared to unvaccinated infected individuals. Vaccinated people still got infected, but their immune systems responded more efficiently, with less collateral inflammatory damage. This dampening of excessive inflammation prevents the cytokine storm that can destabilize vulnerable plaques.

Thrombosis prevention. Influenza infection activates the coagulation cascade, increases platelet reactivity, and promotes endothelial dysfunction. The virus can also trigger Type 2 myocardial infarction through increased metabolic demands on myocardial tissue secondary to fever and tachycardia, coupled with potential hypoxemia from respiratory involvement.

Vaccination reduces the incidence and severity of infections, thereby decreasing the thrombotic triggers. Even when breakthrough infections occur in vaccinated individuals, the attenuated inflammatory response translates to lower thrombotic risk.

Trained immunity. This is where the science gets fascinating. Vaccines induce trained immunity—a form of innate immune memory mediated by epigenetic, transcriptional, and functional reprogramming of innate immune cells such as monocytes, macrophages, and natural killer cells. Unlike adaptive immunity (which is antigen-specific), trained immunity enables a more rapid and effective response to subsequent infections, including pathogens unrelated to the original vaccine.

BCG vaccination, for instance, has been shown to provide cross-protection against diverse respiratory pathogens, potentially reducing the cumulative inflammatory burden from multiple infections over time. Research on BCG-induced trained immunity identified metabolic pathways—including the TCA cycle, glutamine metabolism, and linoleic acid metabolism—that correlate with the magnitude of trained immunity responses. Baseline metabolite profiles can predict trained immunity responses months after vaccination.

While most trained immunity research focuses on BCG, influenza and other vaccines likely induce similar epigenetic reprogramming. This could explain heterologous protection: the observation that certain vaccines provide benefits beyond their target pathogen.

Endothelial function. Direct evidence on vaccination’s effects on endothelial function remains limited, but several lines of research suggest potential benefits. Chronic inflammation is a well-established contributor to endothelial dysfunction, a key early step in atherosclerosis progression and a predictor of future cardiovascular events. By attenuating systemic inflammation, vaccination may indirectly improve endothelial function.

COVID-19 vaccination studies demonstrate that vaccines can reduce inflammatory signatures associated with endothelial injury, including downregulation of adhesion molecules and inflammatory markers that contribute to vascular dysfunction. Influenza vaccination has been hypothesized to modulate inflammation important in myocardial infarction and indirectly prevent thrombosis.

These mechanisms apply across multiple vaccines, not just influenza. Four have demonstrated or suggest cardiovascular protective effects.

The vaccines your cardiologist should be recommending (but probably isn’t)

Four vaccines deserve a place in every cardiac patient’s prevention plan. Here’s the evidence for each—and why uptake remains inadequate.

Influenza (annual). This is the most extensively studied vaccine for cardiovascular protection, with decades of research across observational studies, randomized controlled trials, and meta-analyses. The data are unequivocal: influenza vaccination reduces myocardial infarction risk by 15-45%, major adverse cardiovascular events by 25%, and cardiovascular mortality by 26-41% in high-risk populations.

Despite this, only 27-60% of cardiovascular disease patients are vaccinated annually. A systematic review of heart failure patients found influenza vaccination coverage ranging from as low as 2.5% to as high as 97%, with most studies falling below 60%. In elderly patients post-MI, vaccination rates in some regions hover around 58.9%—better than general cardiac populations but still leaving four out of ten patients unprotected.

If a pharmaceutical drug delivered a 28% reduction in major adverse cardiovascular events and a 41% reduction in cardiovascular mortality with minimal side effects, we would prescribe it universally and consider it malpractice not to. Yet we treat the flu vaccine as optional.

COVID-19 (boosters per CDC guidance). COVID-19 vaccination demonstrates robust cardiovascular protection, particularly in preventing post-infection complications. A large case-control study showed that BNT162b2 or CoronaVac vaccination was associated with lower risk of myocardial infarction or stroke after SARS-CoV-2 infection in patients with cardiovascular disease, with a clear dose-response relationship. For BNT162b2, the risk of post-infection MI or stroke decreased from a hazard ratio of 0.49 (95% CI 0.29–0.84) with one dose to 0.30 (95% CI 0.20–0.44) with two doses and 0.17 (95% CI 0.08–0.34) with three doses. Three doses provide an 83% risk reduction.

A comprehensive meta-analysis demonstrated that COVID-19 vaccination reduced the risk of post-COVID-19 cardiac and thromboembolic outcomes, with meta-analytic subdistribution hazard ratios of 0.22 (95% CI 0.17–0.29) for 0-30 days after SARS-CoV-2 infection. The protective effect was strongest during the acute phase, when cardiovascular complications are most likely.

Yes, COVID-19 mRNA vaccines have been linked to myocarditis and pericarditis, particularly in male adolescents and young adults, with incidence rates of approximately 0.0032% overall and up to 0.0107% after the second dose in adolescents. But context matters: the incidence of myocarditis following COVID-19 infection itself is at least 15-fold higher, ranging from 150 to 4,000 cases per 100,000 infections compared to 1-10 cases per 100,000 vaccinations. In older adults—the population at highest cardiovascular risk—myocarditis risk from vaccination is minimal while COVID-19 severity risk is maximal. The risk-benefit calculation strongly favors vaccination

.Coverage data show 68.4% of adults with coronary heart disease received COVID-19 vaccination, with just over half receiving booster doses. This leaves a substantial proportion of high-risk cardiac patients unprotected against a virus that demonstrably triggers cardiovascular events.

Pneumococcal (PCV20 or PCV15 → PPSV23). Pneumococcal vaccination is recommended for patients with heart failure and other cardiovascular conditions based on the rationale that pneumococcal pneumonia is associated with significant increases in hospitalization and mortality rates in CVD patients. Chronic heart disease qualifies patients for pneumococcal vaccination at younger ages than the general population.

The evidence base for cardiovascular-specific outcomes is less extensive than for influenza, but the biological plausibility is sound: invasive pneumococcal disease triggers similar inflammatory cascades to influenza, potentially precipitating acute cardiovascular events. Current guidelines from major cardiology societies recommend pneumococcal vaccination as part of comprehensive cardiovascular risk reduction strategies.

The coverage is abysmal. Pneumococcal vaccination rates among heart failure patients range from 20% to 84.6% across studies, with many falling below 30%. In one study of cardiovascular disease patients, only 10% had received pneumococcal vaccination. For a vaccine with clear guideline support and minimal risk, this uptake represents a massive failure of preventive care.

RSV (one-time, adults ≥60 with risk factors or ≥75). Respiratory syncytial virus vaccines are the newest addition to the cardiovascular prevention arsenal. RSVPreF3 OA, an adjuvanted RSV prefusion F protein vaccine, was recently approved for adults aged 60 and older following successful Phase 3 trials. The DAN-RSV trial specifically examined cardiovascular outcomes in adults ≥60 years.

Vaccine effectiveness for preventing RSV-related respiratory tract disease hospitalization was 80.0% (95% CI 29.3–96.3) in participants without pre-existing atherosclerotic cardiovascular disease and 100.0% in those with pre-existing cardiovascular disease (though with wide confidence intervals). Notably, the vaccine demonstrated a 9.3% reduction in major adverse cardiovascular events, though this did not reach statistical significance. This is preliminary but intriguing evidence that RSV vaccination may provide cardiovascular benefits beyond infection prevention.

A randomized trial of simultaneous influenza and RSV vaccination in high-risk heart failure patients demonstrated that the primary composite endpoint of all-cause death, heart failure hospitalization, or clinical signs of infection occurred in 59% of vaccinated patients versus 75% in the standard of care group (HR 0.66, 95% CI 0.48–0.92).

RSV vaccination is currently recommended as a one-time dose (not annual) for adults ≥75 years and for adults 60-74 years with high-risk conditions including chronic heart disease. Uptake data are still emerging, but initial implementation suggests low coverage requiring aggressive public health campaigns.

The pattern is clear: strong evidence, guideline support, low implementation. The question is why.

Why cardiologists aren’t talking about this—and how statements like Vembu’s make it worse

If the evidence for vaccination as cardiovascular prevention is this compelling, why do uptake rates remain so low? The barriers operate at multiple levels—and recent controversies amplify them.

Physician-level barriers. Prevention gets deprioritized in acute care settings. When managing a post-MI patient, the immediate focus is dual antiplatelet therapy, beta-blockers, ACE inhibitors, statins, and cardiac rehabilitation referral. Vaccination doesn’t make the discharge checklist, even though the IAMI trial demonstrates it should. Many cardiologists may not be fully aware of the cardiovascular-specific benefits—the IAMI trial is only from 2022, and most cardiology training programs don’t emphasize vaccines as cardioprotection. A survey found that only 61.6% of cardiac patients received vaccination information from their physicians.

Patient-level barriers. Patients often view vaccines as infection prevention, not heart attack prevention, so they don’t prioritize them. Vaccine hesitancy driven by safety concerns and misinformation disseminated through social media adversely affects uptake. For COVID-19 vaccines specifically, concerns about myocarditis—despite the rare absolute risk—contributed to hesitancy even among high-risk cardiac populations.

This is where controversies like Sridhar Vembu’s become directly harmful. When influential figures amplify discredited vaccine-autism links, they erode trust in vaccination broadly—not just for childhood immunizations. Vembu’s posts cited a non-peer-reviewed report co-authored by Andrew Wakefield, whose fraudulent 1998 Lancet paper was retracted. Yet he framed this as “brave doctors questioning dogma.” When a tech entrepreneur with no medical training publicly casts doubt on vaccine safety, it provides social proof for vaccine-hesitant individuals to justify their decisions. That skepticism bleeds into decisions about flu shots, pneumococcal vaccines, and COVID boosters—decisions that directly impact cardiovascular risk in adults.

System-level barriers. Fragmented care separates preventive services from specialty cardiac care. Vaccines are viewed as primary care’s responsibility, not cardiology’s, leading to missed opportunities. Electronic health record systems often lack integrated prompts linking cardiovascular diagnoses to vaccination recommendations. Cost and access barriers persist, particularly in populations without insurance coverage or in regions where vaccine availability is limited.

The solution requires action at all levels: standing orders allowing nursing staff to administer vaccines, co-location of vaccination services within cardiology clinics, and public health campaigns countering misinformation.

Until these changes occur, patients need to advocate for themselves. At your next cardiology appointment, ask: “Am I up to date on my flu, pneumococcal, COVID-19, and RSV vaccines?” Frame it as cardiovascular prevention, not infection control.

The evidence speaks—if we listen

The irony is stark. While a tech billionaire with no medical training commands millions of views spreading vaccine misinformation, landmark cardiovascular trials receive little public attention. The IAMI trial’s 41% reduction in cardiovascular mortality didn’t go viral. The dose-response data showing 83% protection against post-COVID cardiac events didn’t trend on X.

Misinformation drowns out evidence. And the casualties aren’t just childhood vaccination rates—they’re middle-aged adults with coronary disease who skip their flu shots, elderly patients with heart failure who never get pneumococcal vaccines, and post-MI patients who leave the hospital without the intervention that could cut their death risk nearly in half.

The conversation we’re having about vaccines is the wrong one. The conversation we should be having is in the data I’ve presented above. The question is whether cardiologists, patients, and public health systems will act on it before the next patient becomes a preventable statistic.

If you found this useful, please share it.

Evidence over opinions. Clarity over noise. That’s Signal Over Noise.

Share

REFERENCES

1. Fröbert O, Götberg M, Erlinge D, et al. Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Circulation. 2021;144(18):1476-1484. https://doi.org/10.1161/CIRCULATIONAHA.121.057042

2. Warren-Gash C, Hayward AC, Hemingway H, et al. Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study. J Infect Dis. 2012;206(11):1652-1659.

3. Udell JA, Zawi R, Bhatt DL, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013;310(16):1711-1720.

4. Multi-omics analysis reveals COVID-19 vaccine induced attenuation of inflammatory responses during breakthrough disease. Nat Commun. 2024;15(1):3402.

5. Metabolic pathways and trained immunity: Plasma metabolome predicts trained immunity responses after antituberculosis BCG vaccination. PLoS Biol. 2022;20(9):e3001765.

6. Netea MG, Domínguez-Andrés J, Barreiro LB, et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020;20(6):375-388.

7. BNT162b2 or CoronaVac Vaccinations Are Associated With a Lower Risk of Myocardial Infarction and Stroke After SARS-CoV-2 Infection Among Patients With Cardiovascular Disease. J Am Heart Assoc. 2023;12(8):e029291.

8. The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications. Heart. 2024;110(9):567-573.

9. Yadlowsky S, Patel RC, Chua K, et al. Estimation and Validation of Ratio-based Conditional Average Treatment Effects Using Observational Data. J Am Stat Assoc. 2021;116(533):335-352.

10. Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults: A Prespecified Analysis of the DAN-RSV Trial. JAMA. 2025;333(6):512-521.

11. Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions. Clin Infect Dis. 2024;78(3):e1-e12.

12. Simultaneous vaccination against influenza and respiratory syncytial virus in high-risk heart failure patients. Eur J Heart Fail. 2024;26(8):1755-1763.

13. Incidence of Myocarditis/Pericarditis Following mRNA COVID-19 Vaccination Among Children and Younger Adults in the United States. Ann Intern Med. 2022;175(12):1169-1177.

14. Pneumococcal and Influenza Vaccination Coverage in Patients with Heart Failure: A Systematic Review. J Clin Med. 2024;13(11):3029.

15. Pneumococcal and influenza vaccination rates among patients with cardiovascular disease. J Health Sci Med. 2022;5(4):1102321.

16. Effects of Influenza Vaccine on Mortality and Cardiovascular Outcomes in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2021;10(11):e019636.

The reason? Despite being inside a five-star hotel with his own filtration equipment, the indoor AQI measured 130, with PM2.5 at 75 μg/m³. “I can’t see you over there,” he told Kamath during the recording. By his third day in India, his skin had broken out in a rash. His eyes and throat burned. The room circulated outdoor air, rendering his purifier ineffective.

Johnson later wrote on X: “Inside, the AQI was 130 and PM2.5 was 75 μg/m³, which is equal to smoking 3.4 cigarettes for 24 hours of exposure.”

The internet split. Some mocked him for overreacting. Others questioned why he came to India at all.

But Johnson made an observation worth examining: “Air pollution has been so normalized in India that no one even notices anymore despite the science of its negative effects being well known.”

He’s not wrong. In November, thousands ran the Delhi Half Marathon while the city’s AQI exceeded 300—inhaling the equivalent of roughly 30 cigarettes during the race. People go for morning jogs when PM2.5 levels hit 200 μg/m³. Children play outside at recess regardless of air quality. The normalization is complete.

Johnson left after three days. Most people don’t have that option.

1. The invisible scar

We’ve known for years that air pollution causes heart disease. What we didn’t know until recently is that damage starts accumulating at pollution levels we’ve been calling “acceptable.”

A 2025 study in Radiology examined 694 patients using cardiac MRI and found something disturbing: for every 1 μg/m³ increase in long-term PM2.5 exposure, there was measurable diffuse myocardial fibrosis—essentially scarring of the heart muscle. This occurred even in healthy individuals without heart disease, and the relationship held at PM2.5 levels below current regulatory standards.

Delhi’s annual average PM2.5 ranges from 80-120 μg/m³. Residents breathing this air for years are accumulating structural heart damage that predicts future heart failure and arrhythmias. The scarring happens silently, years before the first symptom appears.

Current Indian standards allow annual PM2.5 averages up to 40 μg/m³. The MRI data found no safe threshold. Fibrosis accumulated at every exposure level measured.

2. The plastic in your plaque

While PM2.5 has dominated the pollution conversation, a newer threat has emerged from an unexpected source: the microscopic plastic particles saturating urban air.

A 2024 study in the New England Journal of Medicine examined carotid artery plaques removed from 304 patients during endarterectomy. Researchers found polyethylene microplastics in 58.4% of samples and PVC in another 12.1%. Electron microscopy showed jagged-edged particles embedded within macrophages and scattered through plaque debris.

The clinical outcome was striking. Patients with detectable microplastics in their plaques faced a 4.53-fold increased risk of myocardial infarction, stroke, or death over 34 months of follow-up. Among the largest cardiovascular risk multipliers in recent literature.

These arterial microplastics enter the body primarily through ingestion - contaminated food, bottled water, and packaged products. But inhalation represents a second route. Recent studies by the Indian Institute of Tropical Meteorology found microplastics suspended in Delhi’s breathable air fractions: PM2.5 and PM1. Adults in Delhi inhale an estimated 1,935-5,621 microplastic particles annually. The composition matches what shows up in consumer products and urban waste: polyethylene terephthalate, polyethylene, polyester, polystyrene, and PVC.

The sources overlap with traditional air pollution. Tire abrasion releases polymer particles into PM2.5. Textile manufacturing and household laundry shed synthetic fibers. Plastic waste burning - common in unauthorized colonies - releases respirable microplastic particles. Delhi generates 1,145 tonnes of plastic waste daily, with 635 tonnes being single-use plastics.

Whether these inhaled particles reach arterial plaques, or whether the plaque burden reflects primarily ingested plastics, remains unclear. What’s established: microplastics trigger the same inflammatory mechanisms as PM2.5. Chronic inflammation. Oxidative stress. Endothelial dysfunction. They destabilize plaque and increase thrombotic risk. Unlike PM2.5, which the body can partially clear, microplastics persist indefinitely in tissues.

3. When pollution triggers heart attacks

The chronic effects of pollution—myocardial fibrosis and plastic-laden plaque—set the stage. Acute pollution spikes pull the trigger.

A 2024 case-crossover study from Argentina examined the relationship between wildfire-related PM2.5 spikes and ST-elevation myocardial infarctions. On days when PM2.5 exceeded 20 μg/m³, the odds of STEMI increased 2.2-fold. The risk climbed progressively with higher pollution quartiles. Residents exposed to the highest PM2.5 levels had double the STEMI risk compared to those breathing the cleanest air.

Delhi frequently records PM2.5 levels exceeding 200 μg/m³ during winter months, ten times the threshold where acute cardiac events spike. A comprehensive analysis in Ecotoxicology and Environmental Safety tracked 318,282 UK Biobank participants over 13.5 years. Among participants who developed COPD, each 1 μg/m³ increase in PM2.5 increased their subsequent risk of developing cardiovascular disease by 5.1%. The effect was strongest in women and those over 55 years old.

The temporal pattern matters. Research in Environmental Health examining ischemic stroke cases found that exposure to benzo(a)pyrene (a combustion byproduct common in pollution) increased stroke risk by 10.3% on the same day of exposure and 13.5% across a week-long window. The lag period suggests a cascade: pollution exposure triggers endothelial dysfunction and prothrombotic changes within hours, which manifest as acute events within days.

What’s actually happening at the cellular level? PM2.5 particles smaller than 2.5 micrometers penetrate deep into alveoli and enter the bloodstream. Within hours, these particles trigger oxidative stress, activate inflammatory pathways (particularly IL-6 and TNF-alpha), increase blood viscosity, and promote autonomic nervous system imbalance—shifting toward sympathetic dominance. The cumulative effect: unstable plaques rupture, coronary arteries spasm, and clots form more readily.

Patients with pre-existing plaques are especially vulnerable. A single day breathing Delhi’s peak pollution levels can convert decades of silent arterial disease into an acute myocardial infarction.

4. What you can do

The part you and I can control is exposure. Personal protective measures reduce exposure. They don’t eliminate risk.

A 2020 American Heart Association scientific statement reviewed interventions against particulate matter. HEPA filtration reduced indoor PM2.5 by 58-65% in controlled studies. For people with elevated blood pressure, HEPA units lowered systolic readings by 2-3 mmHg—comparable to low-dose medication effects. N95 masks cut inhaled PM2.5 by 90% when properly fitted. These interventions work.

But they’re insufficient for people with established cardiovascular disease. A study tracking 73,425 U.S. veterans after percutaneous coronary intervention found that each 1 μg/m³ increase in annual PM2.5 exposure raised the risk of heart attack, stroke, or death by 8.7%. Patients exposed to 10 μg/m³ lost 1.1 months of life at five years compared to those breathing 5 μg/m³ air. By 15 years, the difference reached 7.6 months. Even at the relatively low PM2.5 levels in the United States, pollution shortened survival in this vulnerable population.

The post-PCI data matters because it represents patients under optimal medical therapy. Stents placed. Antiplatelet agents prescribed. Risk factors managed. Pollution still accelerated disease progression.

The exercise paradox compounds the problem. Physical inactivity causes cardiovascular disease. Exercise prevents it. But a 2021 European Heart Journal editorial summarized the evidence: exercise in clean air protects the heart, while exercise in polluted air causes harm. The ventilatory rate during exertion increases PM2.5 deposition deep in lung tissue. The cardiovascular benefits of movement don’t outweigh the inflammatory damage from inhaled particulates when air quality deteriorates past certain thresholds.

This creates an impossible choice. Avoid outdoor exercise and lose cardiovascular fitness. Exercise outdoors and accelerate atherosclerosis. Neither option is acceptable.

You’ll hear recommendations about antioxidant supplements. Vitamins C and E. Fish oil. Olive oil. A 2016 review in Biochimica et Biophysica Acta suggested these might protect against short-term pollution exposure by reducing oxidative stress. The hypothesis sounds reasonable.

The clinical trial data tell a different story. Large randomized trials testing antioxidant vitamins for cardiovascular disease prevention have consistently failed. HOPE trial, GISSI trial, Heart Protection Study—vitamin E showed no benefit. Vitamin C showed no benefit. The observational studies showing protective associations were confounded by healthier baseline characteristics in supplement users. People who take vitamins also eat better, exercise more, and see doctors regularly. The supplements weren’t protecting them. Their overall health behaviors were.

Fish oil trials produce similar results. STRENGTH trial, ASCEND trial—no reduction in cardiovascular events. The omega-3 fatty acids that appear protective in observational nutrition studies don’t translate to benefit when isolated in pill form and tested rigorously.

Supplementation won’t counteract chronic pollution exposure. The inflammatory and oxidative stress pathways activated by PM2.5 and microplastics operate at a scale that overwhelms what dietary antioxidants can neutralize.

Personal protective equipment and behavior modification provide marginal risk reduction. For someone breathing heavily polluted air year after year, filtration and masking decrease exposure by perhaps 50-70% during the hours spent indoors or masked. The remaining exposure continues accumulating cardiovascular damage.

The solution isn’t individual. It’s regulatory. Air quality standards need tightening. Enforcement needs strengthening. The evidence showing no safe threshold for PM2.5 exposure argues for pursuing the lowest achievable concentrations, not compromising at levels convenient for industry.

Until that happens, the interventions worth implementing: HEPA filtration in living and sleeping spaces. N95 masks during peak pollution periods. Checking air quality before outdoor exercise and canceling when readings exceed safe levels. Avoiding prolonged outdoor exposure on high pollution days.

But understand what these measures accomplish. They reduce exposure. They don’t restore the cardiovascular health that would exist under clean air. None of this is a cure for the city’s air, and policy will always dwarf personal tactics.

If you found this useful, please share it.

Evidence over opinions. Clarity over noise. That’s Signal Over Noise.

Share

References

All evidence in this newsletter derives from peer-reviewed studies published in leading medical journals. DOI links to original articles are provided for verification.

Myocardial Fibrosis and Chronic Exposure:

• Association between Long-term Exposure to Ambient Air Pollution and Myocardial Fibrosis Assessed with Cardiac MRI. Radiology 2025. https://doi.org/10.1148/radiol.250331

Microplastics and Cardiovascular Disease:

• Marfella R, et al. Microplastics and Nanoplastics in Atheromas and Cardiovascular Events. New England Journal of Medicine 2024. https://doi.org/10.1056/NEJMoa2309822

Acute Cardiovascular Events:

• Impact of wildfires and PM2.5 on ST-elevation acute coronary syndrome in Rosario City, Argentina. International Journal of Environmental Health Research 2024. https://doi.org/10.1080/09603123.2024.2434208

• Dynamic associations between long-term exposure to ambient air pollution and respiratory-cardiovascular diseases: A trajectory analysis. Ecotoxicology and Environmental Safety 2025. https://doi.org/10.1016/j.ecoenv.2025.119329

• Short-term exposure to air pollution and risk of ischemic stroke requiring intravenous thrombolysis. Environmental Health 2025. https://doi.org/10.1186/s12940-025-01230-2

Vulnerable Populations:

• Motairek I, et al. Particulate Matter Air Pollution and Long-Term Outcomes in Patients Undergoing Percutaneous Coronary Intervention. JACC Advances 2023. https://doi.org/10.1016/j.jacadv.2023.100285

• Warburton DER, et al. A Systematic Review of the Short-Term Health Effects of Air Pollution in Persons Living with Coronary Heart Disease. Journal of Clinical Medicine 2019. https://doi.org/10.3390/jcm8020274

Exercise and Air Pollution:

• Münzel T, Hahad O, Daiber A. Running in polluted air is a two-edged sword. European Heart Journal 2021. https://doi.org/10.1093/eurheartj/ehab227

Personal Protective Measures:

• Rajagopalan S, et al. Personal-Level Protective Actions Against Particulate Matter Air Pollution Exposure: A Scientific Statement From the American Heart Association. Circulation 2020. https://doi.org/10.1161/CIR.0000000000000931

Dietary Interventions:

• Tong H. Dietary and pharmacological intervention to mitigate the cardiopulmonary effects of air pollution toxicity. Biochimica et Biophysica Acta 2016. https://doi.org/10.1016/j.bbagen.2016.05.014

Ghuman was a bodybuilding icon—a 40-year-old who had built his physique over decades. Within the same year, five other bodybuilders died suddenly, some barely out of their teens. The news went viral. Your WhatsApp groups lit up with theories: COVID vaccines, whey protein, “overexercising.” Every forward had a different culprit.

I get it. When young, seemingly invincible athletes drop dead, we want a simple villain to blame. The recently published European Heart Journal study on bodybuilding mortality gives us the clearest answer we’ve had.

I’m going to walk through the study’s findings, explain the cardiac conditions that make athletes vulnerable, identify the substances that turn muscle-building into heart damage, and show what this means for screening and prevention. The evidence tells a very different story than the one circulating on social media—and it’s both more specific and more actionable.

1. The bodybuilding mortality study

What the autopsy data actually shows

A 2025 study in the European Heart Journal tracked 20,286 male bodybuilders over 8.1 years—190,211 athlete-years of follow-up.[1] During this period, 121 athletes died. Forty-six of these deaths were sudden cardiac deaths, accounting for 38% of all mortality in this cohort.

The numbers are striking. Among currently competing bodybuilders, the sudden cardiac death incidence was 32.83 per 100,000 athlete-years. Professional bodybuilders faced a 5.23-fold higher risk than amateur competitors. The average age at sudden cardiac death was 34.7 years for those actively competing, though the overall average across all deaths was 42.2 years.

The autopsy findings revealed what was happening inside these hearts. Cardiomegaly—enlarged hearts—was universal. The hearts weighed 73.7% more than normal reference values. Severe ventricular hypertrophy was present in every case. Myocardial fibrosis—scar tissue replacing normal heart muscle—created the substrate for fatal arrhythmias.

Toxicology reports detected anabolic-androgenic steroids in three of five tested cases. At least 16 athletes in the cohort had documented histories of performance-enhancing drug use. The pattern was consistent: structural heart disease, substance exposure, and sudden death during or shortly after intense physical exertion.

The study documented non-cardiac deaths too—suicides, homicides, overdoses, kidney failure. The mental health and substance abuse patterns extended beyond cardiovascular pathology, but that’s a separate discussion.

These numbers are stark. But they don’t tell us why these hearts failed. For that, we need to understand the underlying cardiac conditions that make sudden death possible.

2. The silent cardiac conditions

HCM, ARVC, and the diseases you can’t see coming

Sudden cardiac death in athletes typically results from conditions that remain clinically silent until triggered by exertion. The substrates for these events fall into distinct categories, and understanding them explains why these deaths occur without warning.

Hypertrophic cardiomyopathy (HCM) is the leading cause of sudden cardiac death in athletes under 35.[2] The disease is characterized by asymmetric left ventricular hypertrophy—the ventricular septum thickens disproportionately, creating both mechanical obstruction to blood flow and electrical instability.

The myocardial architecture in HCM is disorganized. Instead of parallel myocyte alignment, the cells arrange in chaotic patterns with increased interstitial fibrosis. This creates the substrate for re-entrant ventricular arrhythmias. During intense exercise, catecholamine release increases myocardial contractility and heart rate. In HCM hearts, this heightened contractile state combined with the disorganized tissue architecture can trigger ventricular tachycardia that degenerates rapidly into ventricular fibrillation.

The clinical challenge is that HCM often presents asymptomatically. Studies show that sudden death is the first manifestation in approximately 30% of cases. The athlete feels fine, performs well, and has no prior symptoms. The diagnosis is missed until autopsy.

Arrhythmogenic right ventricular cardiomyopathy (ARVC) follows a different pathophysiology but produces similar outcomes. The disease involves progressive replacement of right ventricular myocardium with fibrofatty tissue. This replacement creates an arrhythmogenic substrate—the fibrotic regions form electrical barriers that promote re-entrant circuits.

ARVC has a paradoxical relationship with exercise. Mechanical stress from training accelerates myocyte death and fibrofatty replacement. Endurance athletes show higher prevalence, but the repetitive Valsalva maneuvers during heavy resistance training can impose significant right ventricular wall stress. Each training session potentially worsens the underlying pathology.

The right ventricle is technically difficult to image with standard echocardiography, which means ARVC is frequently underdiagnosed until advanced stages. Cardiac MRI has better sensitivity for detecting early fibrofatty changes, but this isn’t part of routine screening.

Ion channelopathies—Long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT)—are genetically determined electrical diseases. The structural heart appears normal on imaging. The problem is in the ion channels that control the cardiac action potential. These conditions are silent at rest. Exertion, stress, and catecholamine surges unmask them. A sprinting finish or a max-effort lift can trigger Torsades de Pointes or polymorphic ventricular tachycardia.

Coronary anomalies, particularly anomalous origin of the left coronary artery from the right sinus of Valsalva, cause sudden death through acute ischemia. During exertion, aortic root dilation compresses the anomalous vessel as it courses between the aorta and pulmonary artery. The resulting myocardial ischemia can trigger ventricular fibrillation. These anomalies are undetectable on ECG or standard echocardiography and require CT or MR angiography for diagnosis.

In athletes over 35, coronary artery disease becomes the dominant substrate.[3]

The bodybuilding mortality study showed the average age of sudden cardiac death was 34.7 years in actively competing athletes but 42.2 years overall—suggesting a transition point where atherosclerotic disease begins to contribute alongside cardiomyopathies.

Varinder Singh Ghuman was over 40. His death could have resulted from longstanding HCM that remained undiagnosed, ARVC accelerated by decades of training, or coronary artery disease compounded by other risk factors.

But the bodybuilding mortality study’s autopsy findings—hearts weighing 73.7% more than normal, severe hypertrophy, extensive fibrosis—suggest that these structural abnormalities weren’t purely from genetic cardiomyopathies. The degree of pathological remodeling points to an additional factor: anabolic-androgenic steroids.

3. The substance cascade

Anabolic steroids, pre-workouts, and the arrhythmogenic perfect storm

The bodybuilding mortality study’s autopsy data revealed hearts that weighed 73.7% more than normal. This isn’t physiological athlete’s heart. This is pathological hypertrophy—and anabolic-androgenic steroids (AAS) are the primary driver.

Anabolic steroids cause direct cardiotoxicity through multiple mechanisms. They induce left ventricular hypertrophy that exceeds physiological adaptation. The myocardium thickens, but the coronary vasculature doesn’t keep pace—creating a supply-demand mismatch. Collagen deposition increases, leading to myocardial fibrosis. This fibrotic tissue creates the substrate for re-entrant ventricular arrhythmias.

AAS accelerate coronary artery disease. They reduce HDL cholesterol, increase LDL oxidation, and promote endothelial dysfunction. Young bodybuilders in their 30s can develop coronary atherosclerosis resembling that of sedentary 60-year-olds. The autopsy reports from the bodybuilding study documented significant coronary artery disease in athletes decades younger than typical CAD patients.

The toxicology findings tell the story: anabolic steroids were detected in three of five tested cases. At least 16 athletes in the cohort had documented performance-enhancing drug use. The real number is certainly higher—many compounds clear rapidly, and post-mortem testing has limitations.

But steroids aren’t the only problem. Pre-workout supplements have become ubiquitous in gym culture, and many contain arrhythmogenic stimulants.

Caffeine in moderate doses (200-400 mg) is relatively safe. The problem is dose-stacking. A pre-workout powder with 300 mg caffeine, combined with an energy drink (160 mg), plus a fat burner (200 mg), delivers 660 mg—enough to prolong the QT interval and increase ectopic beat frequency.

Ephedrine and DMAA (1,3-dimethylamylamine) are more dangerous. Ephedrine increases catecholamine release, raises heart rate and blood pressure, and has been linked to sudden death in young adults. DMAA was banned by the FDA in 2013, but it still appears in supplements sold through online channels. Both compounds synergize with exercise-induced catecholamine surges.

OTC fat burners often combine multiple stimulants—caffeine, synephrine, yohimbine—creating cumulative effects. Add energy drinks to the mix (some bodybuilders consume 3-4 cans daily), and the arrhythmogenic load becomes substantial.

Substance Mechanism Cardiac Effect

The perfect storm occurs when underlying cardiac pathology (HCM, ARVC, ion channelopathy) meets substance-induced remodeling (AAS) and acute sympathomimetic stress (pre-workout stimulants + exertion). A vulnerable heart, a hypertrophied myocardium with fibrotic substrate, a surge of catecholamines—and ventricular fibrillation follows.

So what about the myths flooding your WhatsApp?

4. Debunking the myths

COVID vaccines, whey protein, and ‘overexercising’—what the evidence shows

The viral forwards blame three things: COVID vaccines, whey protein, and “too much exercise.” The data doesn’t support any of these narratives.

COVID vaccines and sudden cardiac death:

The largest study examining this question tracked 1,229 Team USA athletes competing in the Tokyo 2020 and Beijing 2022 Olympics and Paralympics.[4] All athletes were fully vaccinated by Beijing 2022. The study followed them for over a year post-vaccination, monitoring for cardiac events.

The result: zero sudden cardiac arrests, zero sudden cardiac deaths, zero cases of myocarditis, zero cases of pericarditis.

The study was published in Sports Health in 2023. The conclusion was unequivocal: “Complete absence of vaccine-related cardiac complications in elite athletes.”

Vaccine-related myocarditis does occur, but it’s rare—between 2 and 20 cases per 100,000 vaccinated individuals.[5] When it does occur, it’s typically mild and self-limiting. The risk of myocarditis from COVID infection itself is higher—approximately 40 per million infections. For athletes who develop vaccine-related myocarditis, the recommendation is 3-6 months of exercise abstinence, after which full recovery is typical.

The narrative that COVID vaccines caused the bodybuilder deaths doesn’t fit the timeline or the evidence. If vaccines were the culprit, we’d see a spike in sudden cardiac death across all vaccinated athlete populations, not just bodybuilders with documented anabolic steroid use.

Whey protein and cardiac death:

There is no evidence in the medical literature linking standard whey protein supplementation to sudden cardiac death. Whey protein is a food product—a byproduct of cheese production. Consuming 20-40 grams per day doesn’t cause cardiomyopathy, coronary artery disease, or arrhythmias.

The confusion arises because bodybuilders consume whey protein and anabolic steroids and pre-workout stimulants. The visible supplement (the protein powder) gets blamed, while the invisible ones (the injectable testosterone, the oral DMAA) cause the actual damage.

The bodybuilding mortality study’s toxicology findings identified anabolic steroids, not protein powder. The autopsy data showed pathological cardiac hypertrophy and fibrosis—findings consistent with AAS use, not whey consumption.

“Overexercising”:

The narrative that “too much exercise” killed these athletes is partially correct but misleading. Exercise volume alone doesn’t cause sudden cardiac death in healthy hearts.

The problem is the interaction between exercise, underlying cardiac pathology, and substances.

In athletes with HCM, intense exertion triggers arrhythmias by increasing contractility in an already hypertrophied, disorganized myocardium. In athletes with ARVC, repeated exercise accelerates fibrofatty replacement. In athletes with ion channelopathies, the catecholamine surge during a max lift unmasks electrical instability.

Add anabolic steroids—which create pathological hypertrophy and fibrosis—and you’ve converted a normal heart into a vulnerable one. Add pre-workout stimulants, and you’ve amplified the arrhythmogenic trigger.

A 2024 study in the Journal of Clinical Medicine examined long-distance runners and found that excessive training volumes can lead to exercise-induced hypertension, reduced endothelial function, and increased arterial stiffness.[6] This increases the risk of atrial fibrillation and ventricular arrhythmias—but these effects are seen in extreme endurance training over years, not in typical gym-goers.

The bodybuilders who died weren’t just “exercising too much.” They were exercising intensely with underlying cardiac pathology (HCM, ARVC) and substance-induced remodeling (AAS) and acute sympathomimetic stress (pre-workout stimulants). That’s not overexercising—that’s a multi-hit model for sudden death.

Given this evidence, what can be done?

5. Screening and prevention

Why your cardiologist can’t predict sudden death (and what that means for you)

Varinder Singh Ghuman’s death had no warning signs. No prior symptoms. No collapse during a previous workout. Just sudden death.

This is the screening problem.

HCM can be silent until it isn’t. Up to 30% of HCM cases present with sudden death as the first symptom. The disease can be missed on routine physical examination. Even electrocardiograms (ECGs) have limitations—they detect HCM in only 50-70% of cases. The gold standard is cardiac MRI, but obtaining an MRI for every gym-goer isn’t feasible or cost-effective.

ARVC is even harder to detect in early stages. The fibrofatty replacement begins in the right ventricle, which is difficult to image with echocardiography. Cardiac MRI is more sensitive, but again, population-wide screening isn’t practical.

Ion channelopathies can be genetically silent. A resting ECG might be normal. The abnormalities only appear during exercise stress testing or with provocation testing (epinephrine infusion for Long QT, ajmaline challenge for Brugada). Genetic testing can identify mutations, but not everyone with a pathogenic variant develops clinical disease.

Coronary anomalies require imaging—typically CT angiography or cardiac MRI. They won’t be detected on ECG or echocardiography.

So how do we screen?

Pre-participation screening for competitive athletes typically includes:

• Detailed personal and family history

• Physical examination

• 12-lead ECG

The family history is critical. Sudden death in a first-degree relative under age 50 is a red flag. Unexplained syncope during exertion, chest pain, or palpitations warrant further investigation.

The ECG can identify some cases of HCM (voltage criteria for LV hypertrophy, deep T-wave inversions), ARVC (epsilon waves, T-wave inversions in right precordial leads), and Long QT (prolonged QTc interval). But it misses cases too.

Screening considerations:

1. Know your family history. If sudden cardiac death runs in your family, you need screening before intense training.

2. Audit your supplement cabinet. Anabolic steroids cause pathological cardiac remodeling. Pre-workout stimulants containing DMAA, ephedrine, or excessive caffeine increase arrhythmia risk. If you’re using AAS, you need cardiac monitoring—baseline ECG, echocardiogram, and periodic follow-up.

3. Pay attention to symptoms. Chest pain, pressure, or tightness during exertion isn’t normal. Palpitations that persist after exercise aren’t normal. Syncope or near-syncope during lifting isn’t normal. These symptoms demand evaluation—ECG, echocardiogram, possibly cardiac MRI or stress testing.

4. Age matters. If you’re over 35 and pushing high-intensity training, CAD screening (stress testing, calcium scoring, or CT angiography) becomes relevant. The bodybuilding mortality data showed that older athletes died from a mix of cardiomyopathies and coronary disease.

5. Push back on trainers who dismiss symptoms. “No pain, no gain” doesn’t apply to cardiac symptoms. If your chest hurts during a set, stop. If you feel lightheaded or your heart races irregularly, stop. These are warning signs, not weakness.

The collapse-to-defibrillation window determines survival. Data from the sideline management study shows that immediate defibrillation (within 3-5 minutes) is the greatest predictor of survival in sudden cardiac arrest.[3] Gyms should have automated external defibrillators (AEDs) accessible, and staff should be trained in CPR and AED use.

But prevention is better than emergency response. Screening identifies at-risk individuals before they collapse.

Conclusion

The deaths of Varinder Singh Ghuman and five other bodybuilders within a year weren’t caused by COVID vaccines, whey protein, or “too much exercise.” The evidence points to the intersection of three factors: underlying cardiac pathology (HCM, ARVC, ion channelopathies, CAD), substance-induced remodeling (anabolic steroids creating pathological hypertrophy and fibrosis), and acute triggers (intense exertion combined with pre-workout stimulants).

The bodybuilding mortality study’s findings are stark—sudden cardiac death incidence of 32.83 per 100,000 athlete-years in competing bodybuilders, with professional athletes facing a 5.23-fold higher risk. The autopsy data revealed hearts that weighed 73.7% more than normal, with severe hypertrophy and fibrosis creating the substrate for fatal arrhythmias.

The question isn’t whether you should exercise. The question is whether you’re screening for silent cardiac conditions that can turn a workout into a fatal event.

If you found this useful, please share it.

Evidence over opinions. Clarity over noise. That’s Signal Over Noise.

Share

References

1. Mantel Ä, Holmberg M, Andersson DC, et al. Mortality among male bodybuilders: a cohort study. Eur Heart J. 2025;46(3):241-250. doi:10.1093/eurheartj/ehaf285

2. Maron BJ, Desai MY, Nishimura RA, et al. Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2024;83(5):1-24. doi:10.1016/j.jacc.2023.10.032

3. Yeo TJ, Sharma S. Sideline management of sudden cardiac arrest in athletes. Video J Sports Med. 2025;5:26350254251329104. doi:10.1177/26350254251329104

4. Daniels CJ, Rajpal S, Greenshields JT, et al. Cardiovascular outcomes following COVID-19 vaccination among elite athletes: 1-year follow-up analysis of Team USA participants. Sports Health. 2023;15(6):795-801. doi:10.1177/19417381231208677

5. Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Curr Cardiol Rep. 2022;24(10):1383-1391. doi:10.1007/s11886-022-01801-6

6. Małek ŁA, Barczuk-Falęcka M, Werys K, et al. Exercise-induced blood pressure in recreational long-distance runners and its relationship to arterial stiffness and cardiac biomarkers. J Clin Med. 2024;13(8):2184. doi:10.3390/jcm13082184

I got to read extensively about coronary artery calcium over the last few weeks, and I can tell you the reality is more nuanced. When used in the right patients, CAC is the single best test we have for determining who actually needs aggressive heart disease prevention—it changes treatment decisions in nearly half of people who get it. But it doesn’t work equally well for everyone, and a zero score doesn’t mean you’re immune from heart disease.

In this newsletter, I’ll walk you through when CAC meaningfully changes management versus when it offers false reassurance.

1. The power and limits of a zero calcium score

CAC=0 represents the strongest negative predictor we have in cardiovascular medicine, but this protection comes with an expiration date.

In people without symptoms, annual heart attack rates with CAC=0 average 0.027%—translating to 99.4% survival over 10 years¹. The CAC Consortium tracked thousands of individuals and found death rates of only 0.32 to 0.43 per 1,000 person-years when calcium was absent.¹ These numbers explain why many cardiologists call it the “power of zero.”

But this warranty period shortens dramatically depending on your risk profile. If you have diabetes, that protective window shrinks to just 3-4 years compared to 5-7 years for non-diabetics.² The Multi-Ethnic Study of Atherosclerosis revealed that women with diabetes maintain CAC=0 protection for 4.3 years versus 6.9 years without diabetes. For men with diabetes, the warranty drops to 3.1 years compared to 4.8 years². The message: if you have diabetes and get a zero score, you’ll need another scan in 3 years rather than waiting the typical 5 years.

Current smokers with CAC=0 face a particularly striking risk elevation—2.10 times higher cardiovascular death rates compared to nonsmokers with zero calcium.³ That risk level matches what nonsmokers experience when their calcium scores reach 100-399. The “power of zero” essentially evaporates if you continue smoking.

A common scenario that illustrates the complexity

Last week, I wrote a thread on Lp-a, and someone posted this in reply

This captures the exact anxiety many people face when they discover elevated Lp(a)—a genetic risk factor they can’t diet or exercise away. The question becomes: should he get a calcium score, and what would it actually tell him?

Two recent studies clarified how Lp(a) and calcium scores interact in ways that challenge what many people assume. A 2025 study in the Journal of Clinical Lipidology examined how these markers predict atherosclerotic cardiovascular disease.⁴ High Lp(a) alone carried an odds ratio of 1.36 for prevalent disease, while positive calcium scoring showed an odds ratio of 1.79. When both were elevated together, the odds ratio jumped to 2.40.

But here’s what matters for this person’s immediate question: high Lp(a) with CAC=0 did NOT significantly increase the odds for cardiovascular disease.⁴

The 2022 JACC analysis of 6,590 participants showed something similar.⁵ Elevated Lp(a) increased cardiovascular risk overall, but among those with CAC=0, elevated Lp(a) failed to stratify near-term risk further. The multiplicative effect only emerged when both markers were elevated—patients with Lp(a) in the highest quintile AND calcium scores exceeding 100 had 10-year risk above 15%, while those with low Lp(a) and CAC=0 stayed below 2%.⁵

These findings reveal something fundamental: Lp(a) and calcium measure different things. Roughly 25% of patients with CAC=0 have Lp(a) exceeding 40 mg/dL, and 15% maintain zero calcium despite Lp(a) above 40.⁵ Lp(a) predicts who will develop atherosclerosis in the future, while calcium measures who already has established disease right now.

For this 46-year-old, a zero calcium score would mean his current risk remains low despite the genetic predisposition—likely low enough to defer statins while maintaining aggressive lifestyle management. But the elevated Lp(a) means atherosclerosis development continues in the background, making rescanning in 3-5 years critical to catch disease before it becomes clinically significant.

The most important limitation: among patients with CAC=0 followed in MESA, 19% of all coronary events over 10 years occurred before the recommended 3-5 year rescan window.⁶ Zero calcium provides time-limited reassurance, not lifetime immunity.

2. What CAC detects versus what it misses

Here’s what you need to understand about calcium scoring: it only shows you the calcified part of plaque buildup. Calcium represents roughly one-fifth of total plaque burden, and this limitation changes how useful the test is depending on your age and symptoms.

If you’re younger than 40, calcium scoring often misses the problem entirely. Among patients under 40 with serious coronary blockages, 58% have zero calcium compared to only 5% of those over 70.⁷ Young adults develop soft, non-calcified plaque that takes decades to calcify. A zero score in your 30s doesn’t exclude significant disease—it just means the disease hasn’t been there long enough to turn into calcium yet. This explains why calcium scoring works poorly for early detection in younger populations.

If you have symptoms—chest pain, shortness of breath, unusual fatigue—calcium scoring isn’t the right test. You need imaging that shows the actual blockages, not just calcium deposits. Seven percent of symptomatic patients with CAC=0 harbor significant soft plaque when you look with more detailed imaging.⁸ South Asian populations show even higher rates—28.8% demonstrate soft plaque despite zero calcium, including some with blockages exceeding 50%.⁹ If you’re experiencing symptoms, your physician should order tests that visualize the full picture of your coronary arteries, not just the calcified portions.

Once calcium appears, understanding how it progresses helps with rescanning decisions. On average, calcium scores increase 20-25% annually, though individual patterns vary widely.¹⁰ Among 3,116 people with initially zero calcium followed for 10 years, about half developed detectable calcium, roughly one-third progressed to scores above 10, and nearly one in ten reached scores exceeding 100.¹¹ The rate accelerates over time—2-3% per year in the first two years, climbing to 4-5% per year between years 4-10.¹¹

What this means practically: if your first calcium score comes back at zero, your risk of developing significant calcium (scores above 100 that change treatment recommendations) within 3-5 years runs below 10%. But that probability increases the longer you wait between scans, which is why the warranty period concept matters. A zero score today doesn’t prevent calcium accumulation tomorrow.

Something unexpected from the progression data: how fast your calcium grows matters less than where it stands right now. Your most recent absolute calcium score predicts future cardiovascular events better than knowing whether you progressed rapidly or slowly.¹² This suggests focusing on your current disease burden rather than obsessing over whether last year’s score of 50 jumped to 75 or crept to 60.

For lean, metabolically healthy individuals with elevated lipids but no obesity, metabolic syndrome, or insulin resistance, calcium scoring likely tells you more than lipid panels alone. A trial of 100 lean subjects with BMI below 25 and LDL cholesterol between 200-600 mg/dL found that existing plaque predicted future plaque progression over 12 months while LDL-C and ApoB levels did not.¹³ In this specific phenotype, knowing whether atherosclerosis already exists appears more important than measuring cholesterol particle concentrations.

3. When CAC creates clarity versus when it misleads

CAC provides maximum clinical value in a precisely defined population: intermediate-risk primary prevention patients aged 40-75 where treatment decisions remain genuinely uncertain after considering all other factors.

Here’s where calcium scoring actually changes decisions: In studies of people with intermediate risk—those genuinely uncertain about whether to start statins—about half get a zero calcium score.¹⁴ For these people, their near-term heart attack and stroke risk runs low enough that deferring medications makes sense while focusing on lifestyle.

The other half discover they have calcium, and this is where the conversation shifts. About one in four to one in three people find their calcium scores exceed 100, revealing enough established disease that starting medications becomes clearly beneficial—not based on risk calculators or theoretical models, but because you can see the atherosclerosis already present in your arteries.¹⁴ The test essentially splits people who thought they were in a gray zone into two clearer groups: those who can reasonably wait on medications, and those who have enough disease that medications offer tangible benefit.

Several populations derive limited or misleading information from calcium scoring. Patients under age 40 show that 58% with obstructive coronary disease have CAC=0—the test’s negative predictive value collapses in young adults whose atherosclerosis remains predominantly non-calcified.⁷ Symptomatic patients require functional or anatomic assessment beyond calcium quantification because calcium scoring shows only 40% specificity and 68% positive predictive value for obstructive disease when symptoms are present.¹⁵ Very high-risk patients with 10-year cardiovascular risk exceeding 20% already have indications for statins regardless of what calcium scoring shows. Patients already on maximal preventive therapy gain little from confirming plaque burden that won’t change management unless calcium exceeds 1,000, which might prompt consideration of PCSK9 inhibitors.¹⁶

The resolution for someone with well-controlled diabetes, lifestyle-managed dyslipidemia, high Lp(a), lean BMI, regular exercise, and preference for evidence over reflexive pharmaceutical intervention comes down to three specific scenarios. A score of zero would justify deferring statin therapy despite diabetes and high Lp(a), though rescanning in 3 years remains appropriate given these risk factors shorten the warranty period to 3-4 years. The new data from JACL 2025 clarifies that high Lp(a) with CAC=0 doesn’t increase near-term risk—calcium presence matters more than atherogenic particle concentration for immediate management decisions.⁴

A score of 100-399 would clearly indicate statin benefit with numbers needed to treat ranging from 46-84, potentially overcoming pharmaceutical skepticism through visualization of established disease rather than theoretical risk calculations.¹⁷ A score of 1,000 or higher would establish very-high-risk status warranting LDL cholesterol targets below 55 mg/dL and consideration of PCSK9 inhibitors if targets remain unmet despite statins plus ezetimibe.¹⁶

4. Addressing two critical misconceptions

Misconception 1: CAC should be universal screening for all adults

Online advocates claim calcium scoring should replace traditional risk assessment for everyone, citing superior predictive accuracy and the “power of zero.” This position misreads what the evidence actually supports.

CAC functions as precision medicine for cardiovascular prevention in intermediate-risk populations where treatment decisions lack clarity, not as universal screening replacing clinical judgment. The biomarker works best when clinical uncertainty exists—when you and your physician genuinely aren’t sure whether starting preventive medications makes sense based on other factors. For someone already at high risk with clear medication indications, calcium scoring just confirms what we already know. For someone at very low risk, the test rarely changes management because preventive medications weren’t indicated anyway.

The radiation exposure argument against universal screening holds less weight than critics claim. Modern scanning protocols deliver approximately 1 mSv of radiation—equivalent to four months of natural background exposure.¹⁸ The estimated lifetime cancer risk from this radiation dose runs between 1-2 cancers per 100,000 scanned individuals.¹⁸ This risk sits substantially lower than the diagnostic benefit of accurate risk reclassification in 30-40% of appropriately selected patients. But radiation becomes less justifiable when applied to populations where the test won’t change management decisions.

Misconception 4: CAC=0 means lifetime immunity from heart disease

The zero score provides powerful reassurance, but treating it as lifetime immunity misunderstands how atherosclerosis develops over time.

In asymptomatic populations, CAC=0 delivers 99.4% 10-year survival with annual coronary event rates averaging 0.027%.¹ These numbers justify calling zero calcium a “warranty” against near-term cardiovascular events. But warranty periods have expiration dates that depend on your other risk factors.

For people with diabetes, that warranty runs 3-4 years rather than the 5-7 years seen in non-diabetics.² Current smokers with CAC=0 face 2.10-fold increased cardiovascular mortality compared to nonsmokers with zero calcium—risk equivalent to nonsmokers with calcium scores between 100-399.³ High Lp(a) combined with other risk factors drives ongoing atherosclerosis development even when today’s calcium score shows zero.

The Multi-Ethnic Study of Atherosclerosis revealed that 19% of all 10-year coronary events in CAC=0 patients occurred before the recommended 3-5 year rescan.⁶ Among 3,116 MESA participants with baseline CAC=0 followed for 10 years, 53% developed detectable calcium, 36% progressed to scores above 10, and 8% reached scores exceeding 100.¹¹ Zero calcium today doesn’t prevent calcium accumulation tomorrow—it just tells you where you stand right now.

The appropriate interpretation: CAC=0 indicates current low risk that justifies deferring preventive medications in many situations, but ongoing risk factor management remains critical, and rescanning at appropriate intervals based on your risk profile ensures the zero score hasn’t changed to something that would alter treatment decisions.

If you found this useful, please share it.

Evidence over opinions. Clarity over noise. That’s Signal Over Noise.

Share

References

1. Blaha MJ, Cainzos-Achirica M, Greenland P, et al. Role of coronary artery calcium score of zero and other negative risk markers for cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2016;133(9):849-858.

2. Malik S, Zhao Y, Budoff M, et al. Coronary artery calcium score for long-term risk classification in individuals with type 2 diabetes and metabolic syndrome from the Multi-Ethnic Study of Atherosclerosis. JAMA Cardiol. 2017;2(12):1332-1340.

3. McEvoy JW, Blaha MJ, DeFilippis AP, et al. Coronary artery calcium progression: an important clinical measurement? A review of published reports. J Am Coll Cardiol. 2010;56(20):1613-1622.

4. Park HE, Kim M, Choi SY. Association of lipoprotein(a) and coronary artery calcium with atherosclerotic cardiovascular disease. J Clin Lipidol. 2025;19(2):e234-e242.

5. Mehta A, Rigdon J, Tattersall MC, et al. Association of lipoprotein(a) and coronary artery calcium score for predicting cardiovascular disease events in adults (from the Multi-Ethnic Study of Atherosclerosis [MESA]). Am J Cardiol. 2022;150:1-8.

6. Nasir K, Bittencourt MS, Blaha MJ, et al. Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology/American Heart Association Cholesterol Management Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2015;66(15):1657-1668.

7. Fernández-Friera L, Fuster V, López-Melgar B, et al. Normal LDL-cholesterol levels are associated with subclinical atherosclerosis in the absence of risk factors. J Am Coll Cardiol. 2017;70(24):2979-2991.

8. Gottlieb I, Miller JM, Arbab-Zadeh A, et al. The absence of coronary calcification does not exclude obstructive coronary artery disease or the need for revascularization in patients referred for conventional coronary angiography. J Am Coll Cardiol. 2010;55(7):627-634.

9. Valenti V, Ó Hartaigh B, Heo R, et al. A 15-year warranty period for asymptomatic individuals without coronary artery calcium: a prospective follow-up of 9,715 individuals. JACC Cardiovasc Imaging. 2015;8(8):900-909.

10. Budoff MJ, Young R, Lopez VA, et al. Progression of coronary calcium and incident coronary heart disease events: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2013;61(12):1231-1239.

11. Lehmann N, Erbel R, Mahabadi AA, et al. Value of progression of coronary artery calcification for risk prediction of coronary and cardiovascular events: result of the HNR study (Heinz Nixdorf Recall). Circulation. 2018;137(7):665-679.

12. Min JK, Lin FY, Gidseg DS, et al. Determinants of coronary calcium conversion among patients with a normal coronary calcium scan: what is the warranty period for remaining normal? J Am Coll Cardiol. 2010;55(11):1110-1117.

13. Bhanpuri NH, Hallberg SJ, Williams PT, et al. Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year: an open label, non-randomized, controlled study. Cardiovasc Diabetol. 2018;17(1):56.

14. Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012;308(8):788-795.

15. Dedic A, Lubbers MM, Schaap J, et al. Coronary CT angiography for suspected ACS in the era of high-sensitivity troponins: randomized multicenter study. J Am Coll Cardiol. 2016;67(1):16-26.

16. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary. Circulation. 2019;139(25):e1046-e1081.

17. Mortensen MB, Falk E, Li D, et al. Statin trials, cardiovascular events, and coronary artery calcification: implications for a trial-based approach to statin therapy in MESA. JACC Cardiovasc Imaging. 2018;11(2 Pt 1):221-230.

18. Einstein AJ, Henzlova MJ, Rajagopalan S. Estimating risk of cancer associated with radiation exposure from 64-slice computed tomography coronary angiography. JAMA. 2007;298(3):317-323.

Subscribe now